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1 Introduction 
 
Cancer is the second leading cause of death in the western world after heart disease. Classical 
cancer treatments, including radiation- and chemotherapy, can have many unwanted side 
effects, often weakening the patient tremendously and reducing the patient’s quality of life [1, 
2]. The efficiency of drugs used in chemotherapy, and therefore also the amount of the active 
agent needed, is greatly influenced by the molecular and biochemical properties of the cancer 
to be eradicated. Different cancer subtypes contain their own subset of abnormalities in the 
genetic code which change signaling pathways, create proteins in wrong amounts or even 
proteins lacking any useful structure [3]. It is therefore essential to choose the right 
medication for a patient with a certain type of cancer to achieve best results, and also to 
minimize the amount of the drug that has to be administered.  
The overall rate of survival has risen constantly due to improvements in diagnosis and 
treatment made possible by the advances of cell, molecular, computational, developmental, 
and structural biology as well as biochemistry, genetics, molecular biophysics, bioinformatics 
and chemometrics. These once separate fields of activity have molten together in the last 
couple of years, urged by the need for an interdisciplinary approach to understand the 
complex patterns behind cancer cell biology. One example for this is the molecular 
characterization of a tumor to determine which drug or combination of therapies is the most 
effective for a patient. Research is done with state of the art DNA microarrays [4] (chapter 
3.4), increasing the knowledge of the genetic abnormalities responsible for certain subtypes of 
cancer. This information can then be used to design small, affordable diagnostic microarrays 
for medical applications. The first DNA based diagnostic biosensors will be approved for use 
in these fields in the very near future (chapter 3.4.5). These new devices have the promise of 
helping to further increase the effectiveness of anti-cancer therapies and to increase overall 
survival rates [5-7].  
Once a cancer type is recognized, it has to be treated with the right drug. The use of classical 
chemotherapy drugs including the classical DNA alkylating agents like cis-platin or 
triethylmelanine, the antimetabolites like pyrimidin- or pyrin-analogues and enzymes like L- 
asparaginase is often followed by many side effects as these drugs can also affect normal cells. 
When cis-platin, the most used chemotherapy agent, enters the cell nucleus, the chloro ligands 
are substituted by two adjacent guanine bases on a DNA strand. This makes the DNA duplex 
bend and unwind at the site of cisplatin attachment. The high-mobility-group domain (HMG) 
proteins then become attached to the structural damage, hereby preventing cancer cell 
replication [8]. As was reviewed in the Current Medicinal Chemistry – Anti Cancer Agents  
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journals (e.g. [9-11]), targeted therapies using novel drugs reduce side effects as scientists try 
to design these drugs so that they target properties unique to cancer, e.g. they disrupt certain 
signaling pathways [12], and thus avoid normal cells. One example is Gleevec, a drug 
designed to work against a certain, deadly type of leukemia (CML). It was introduced by 
Novartis in 2001 and revolutionized the treatment of CML. Gleevec works as a signal 
transduction inhibitor that interferes with cell signaling pathways in tumor development, 
blocking the abelson-tyrosinkinase without interfering with other tyrokinases abundant in all 
cells. Other so called smart drugs followed, most of them far less successful. Iressa for 
example, which received approval from the U.S. Food and Drug Administration in 2003, is a 
drug targeted at the epidermal growth factor receptor (EGFR), a protein involved in cancer 
cell growth. However, chemotherapy together with Iressa did not achieve better results than 
chemotherapy alone during phase III of clinical trials. This example, among others, has shown 
that a lot of research is still needed to truly understand the complex machinery of cancer 
creation and proliferation [13, 14].  
The role of chemometrics and bioinformatics in this research is to design and select optimal 
measurement procedures and experiments and to maximize the information which can be 
extracted from data. The application of a multi step analysis of the very complex multivariate 
data gathered in microarray experiments has to be done in an optimal way to obtain 
informative results that can be used to interpret the biological background of the data. The 
elements which are defining the speed at which progress is made in the bioanalytics sector are 
now the analysis and interpretation of this complex data and far less often technical reasons 
[15]. The optimal application of chemometrics is important during the research, the 
development and the design of  DNA biosensors as well as during analysis of actual samples 
from patients as it should never be forgotten that the data is gathered using tumour samples 
obtained from individual cancer patients with their own lives and hopes. 
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2 Aims & Scope 
 
The aim of this work was to create and enhance chemometric methods for the analysis of 
microarray data, to apply these methods, in order to obtain information on relevant genes 
useful for the characterization of different cancer subtypes and to use these genes for the 
creation of classifiers for the discrimination of unknown cancer samples. 
The main focus was put on the development of quality control routines for Affymetrix 
microarrays, which are the best developed DNA biosensor platform and will probably be the 
first technology applied in real world diagnostics in the very near future. Routines include 
quality control procedures for the processing of inhomogeneous background signals and 
procedures for obtaining information on the genetic traits of pediatric acute lymphocytic 
leukemia. 
Several hundred Affymetrix U133 microarrays were analyzed to create novel methods for the 
automatic detection of signal artifacts and to process these chips to remove inhomogeneous 
signal background and differences in signal scaling. These methods were applied on replicate 
measurements to show their efficiency in raising the quality of the obtained signals. Further, 
the methods were tested on microarrays with known and unknown defects to evaluate their 
ability to detect them. Different tools have been created for analysis, management and 
processing of data. A tool was created to facilitate the design of probe sequences for a custom 
made microarray. 
A pediatric leukemia dataset was analyzed with the intention of selecting genes best suited for 
discriminating different leukemia subtypes. This process was also used to compare different 
gene selection algorithms as well as different methods for the calculation of gene specific 
expression signals.  
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3 Theory  
 
3.1  Nucleic Acid: Structure and Function 
 
Nucleic acids as carriers of the genetic information can be subdivided into two classes:  
• deoxyribonucleic acid (DNA) with the sole purpose of storing information; 
• ribonucleic acid (RNA) with a role in gene-expression and protein biosynthesis.  
 
The genomic DNA is located nearly solely in the chromosomes of the nucleus of eukaryotic 
cells, whereas RNA can be found in the nucleus as well as in the cytoplasm [16]. 
DNA is an unbranched biopolymer composed of nucleotides and can reach considerable 
length. Each nucleotide consists of sugar (deoxyribose), a nitrogen containing base attached to 
the sugar, and a phosphate group. There are four different types of nucleotides found in DNA, 
differing only in the nitrogenous base. DNA can consist of the two purin-bases adenine (A) 
and guanine (G) and the two pyrimidine-bases cytosine (C) and thymine (T). RNA contains 
ribose as sugar component, and the structurally similar uracile (U) instead of thymine. The 
polymer is created by bondage of the sugar groups through the phosphate groups. The genetic 
information of the organism is stored in the sequence of the four bases, read in the same 
direction as it was synthesized, that is, from the 5’ to the 3’ – end. DNA is synthesized by 
recurrent attachment of an incoming deoxynucloside triphosphate to the free 3’ OH-group of 
the growing DNA sequence. 
DNA has a double helix structure in a natural surrounding, in which two complimentary DNA 
single strands are wound around the same axis. 
 
 
Fig. 3.1 DNA structure [from chromosome.com] 
 
The resulting macromolecule has a polar and a negatively charged surface created by the 
outside lying sugar-phosphate backbone. The interactions between the two DNA strands are 
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based on hydrogen bonds between the nucleic acid bases adenine and thymine on one hand, 
and guanine and cytosine on the other. 
3.2 Gene Expression 
 
Functional regions of the DNA are called genes, most genes coding proteins. Each amino acid 
component of a protein is coded by three base pairs in the DNA (codon). The information of a 
gene is transferred into a messenger RNA (mRNA). The RNA is then transformed multiple 
times and transferred to the ribosomes. Here it is read and the proteins are synthesized.  
Proteins are the building blocks of the organic tissues and fluids; they provide most of the 
molecular machinery. Different genes are expressed in different cell and tissue types and at 
different developmental stages. Cells at certain locations thus produce the proteins they need 
at certain times [16].  
 
 
Fig. 3.2 Transcription of information from DNA to mRNA and synthesis of 
polypeptides in the ribosome [source: Genentech]. 
 
Analysis of variations in gene expression can lead to an understanding of disease states, 
targeting of drugs to specific cells, tissues or individuals, development of agricultural 
products, etc. [17, 18]. Gene expression can be quantified by using microarrays in order to 
analyze simultaneously the amount of a large multitude of different mRNA in a sample.  
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This can then be the basis to gain more information on certain tissue types like tumors [19, 
20]. More information on nucleic acid analytics is given by Haberhausen et al. [21] , Pingoud  
and Urbanke [22],  and Christopoulos [23]. 
 
 
3.3 Cancer 
3.3.1 Overview 
 
The word “cancer” is a generic term describing more than 100 forms of the disease that can 
arise in most tissues [24]. Five general subgroups can be defined [American Cancer Society, 
ACS]: 
 
Carcinoma -  a tumor derived from epithelial cells - those cells that line the surface of the 
skin and the organs, also the surfaces of the digestive tract and the airways. 
This is the most common cancer type and represents about 80-90% of all 
cancer cases reported. 
 
Sarcoma -   a tumor derived from muscle, bone, cartilage, fat or connective tissues. 
 
Leukemia -  a cancer derived from blood cells or their precursors. The cells that form both 
white and red blood cells are located in the bone marrow.  
 
Lymphoma - a cancer of bone marrow derived from cells that affect the lymphatic system.  
 
Myelomas -  a cancer involving the white blood cells responsible for the production of 
antibodies. 
 
Each form of cancer can have very different properties, although the processes through which 
these diverse tumors arise are quite similar [25, 26]. The human body consists of 30 trillion 
cells which work together, they only proliferate when get the signal to do so. It is essential for 
certain tissues to retain their size and properties in order  to work in unison with the rest of the 
body. Cancer cells, on the other hand, leave this strict ruling, following their own schemes for 
reproduction. They can leave their site of origin and invade other tissues, often disrupting 
their function and thus becoming lethal [27]. Every part of the body can develop a primary 
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tumor, the most prominent regions being the lung (through smoking), the breast in women 
and the prostate in men (see figure 3.3). The probability of developing a certain cancer type is 
linked to many different factors like environment, lifestyle, genetic makeup and especially 
age.  
 
 
 
Fig. 3.3 Incidence rates of certain cancers diagnosed in Europe. Rates are calculated 
by division of the number of new cancer cases observed during the year 1998 
by the corresponding number of people in the population at risk. Results 
expressed as an annual rate per 100.000 persons at risk [28].  
 
These facts have been known for a long time, but the research during the last couple of years 
has shed light into the molecular sources of these characteristics. It is now common 
knowledge that the malignant transformation of a cell is the product of an accumulation of 
mutations of certain genes within it. If a gene is mutated, its function may be disrupted; it may 
be present at the wrong numbers producing a wrong amount of a protein; it may be located at 
the wrong area of the genome or it may be missing completely. Proto-oncogenes encourage 
the proliferation of the cell, tumor suppressor genes inhibit it. Together, these two classes of 
genes keep the cell in balance, making it a functioning part of the body [28, 29]. Mutated 
proto-oncogenes can become carcinogenic oncogenes, driving excess multiplication. Tumor 
suppressor genes can be switched off by mutation, also contributing to a forming malignancy. 
At least half a dozen growth-regulating genes have to be affected so that a malignant 
development can start. 
Brain, nervous system 8.82 6.64 Brain, nervous system 
Mouth, oral cavity    23 
5.97 Mouth, oral cavity 
Lung    82.52 23.87 Lung 
Stomach    22.95 
15.01 Stomach 
Bladder   30.99 
109.84 Breast 
8.56 Bladder 
Testis  4.81 
Prostate  78.94 
Colon / Rectum   61.82 
54.43 Colon / Rectum 
49.28 Uterus / Ovary 
Melanoma of the skin  8.96 11.38 Melanoma of the skin 
Leukemia  13.35 9.95 Leukemia 
Lymphoma   18.12 14.43 Lymphoma 
Incidence rates of cancer diagnosis in 1998 in Europe per 100.000 persons 
Source: The European Commission Health Monitoring Program  
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Signals from outside are forwarded into the cell by means of a pathway built by many 
different genes. As members of this chain become deregulated, the net signal the cell receives 
can be distorted, leading, for example, to excessive multiplication. One example is the ras 
family of genes which are members of one certain signaling chain. Hyperactive ras proteins 
are found in about a quarter of all human tumors [30, 31].  
 
 
Fig. 3.4 Signal cascade from a cell receptor through a pathway built by many 
different genes down to the activation of interferon gamma. Hyperactive ras 
proteins are found in a quarter of all human tumors [Novartis] 
 
Signals between cells can be forwarded by means of certain proteins acting as growth-factors, 
docking onto the receptors of cells surrounding the one emitting these molecules. The myc 
proteins are normally only created when growth-factors dock onto the cell. But many cancers, 
especially those of the tissues producing blood, have a constantly high level of myc which 
then urges the cell to proliferate. Oncogenes can also stimulate a cell into producing too much 
of these growth-factors, thus affecting all cells surrounding it. Examples are sarcomas and 
gliomas. Genes creating the receptors of a cell may also be mutated, forming receptors that 
forward a signal into the cell that has never actually been received.  
Besides interpreting wrong growth signals, a cell must also become deaf to growth breaking 
signals from its surrounding neighbor cells. These inhibitory signals are also transmitted 
through the cell starting at receptors, just as growth signals do. This signal processing chain 
has to be compromised, too. One example are colon cancer cells inactivating a gene which 
create receptors for the transforming growth factor beta (TGF-β) which can stop a cell from 
growing. It could be shown through experiments that the introduction of a missing gene 
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related to the stopping of growth can restore the function of the cell in this regard, changing it 
into a healthier one [32]. The identification of a deregulation of a certain gene using the 
microarray technology can therefore help in designing novel genetic therapies and in the 
development of signaling molecules which can be applied to the tumor for signal induction 
[33].  
3.3.2 Leukemia 
3.3.2.1 Introduction 
 
Patients with leukemia produce abnormal blood cells, called leukemia cells. These cells may 
function almost normally but change the general composition of the blood and disturb the 
function of the other blood components like red blood cells, normal white blood cells and 
platelets. Chronic leukemia is a form of leukemia where patients may not feel any immediate 
symptoms. The symptoms arise slowly together with the increasing number of leukemia cells 
in the blood. In acute leukemia, the leukemia cells are so abnormal that they cannot perform 
their original function. Their number increases rapidly, clear symptoms arise [3]. The types of 
leukemia are also grouped by the type of white blood cell that is affected; leukemia can arise 
in lymphoid and myeloid cells. 
 
 
Fig. 3.5 Blood cells maturing from stem cells. 
Pluripotent stem cells branch off into myeloid and lymphoid stem cells, becoming blast cells, and 
then becoming red blood cells, white blood cells, or platelets.  [Source: American Cancer Society]. 
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The four common types of leukemia are: 
 
• Chronic Lymphocytic Leukemia (CLL) 
 Most people diagnosed with this disease are over age 55. 
 
• Chronic Myeloid Leukemia (CML)  
 This illness affects mainly adults. 
 
• Acute Lymphocytic Leukemia (ALL) 
 It is the most common type of leukemia in young children. About 650 children below 
the age of 15 fall ill with leukemia each year in Germany each year, 83% of these 
having ALL and 15% AML. 
 
• Acute Myeloid Leukemia (AML) 
 This illness affects mostly adults; children are only affected in seldom cases [34]. 
 
There are several other rare leukemia types like the hairy cell leukemia. Myeloid and 
lymphoid leukemia can be discerned based on morphological, cytochemical and 
immunological differences.  
Lymphocytes originate in the bone marrow and are involved in the immune system. 
Depending on the follow-up transformation of these cells, they either become T-cells or B-
cells. Those cells passing through the thymus become T-cells, responsible for cell-mediated 
immunity. Other lymphocytes pass through the bursa equivalent organ becoming B-cells 
which produce antibodies. 
Risk factors for falling ill with leukemia include high levels of radiation (as experienced in 
Japan at the end of WWII and in Chernobyl 1986 [35] ), certain chemicals like benzene and 
certain genetic traits. Patients with pediatric ALL have a mean age of 4 years [36]. The 
majority of the other leukemia cases arise at a higher age as seen in figure 3.6. 
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Fig. 3.6 Incidence rates of leukemia in the U.S.A. 1992-2000. Pediatric ALL 
incidences are clearly visible as are the higher incidence rates for men. 
[Source: Surveillance, Epidemiology, and End Results (SEER) Program] 
 
 
3.3.2.2 Diagnosis 
 
Patients may only feel weaker than usual if they have chronic leukemia, or they may feel 
several symptoms equal to having a bad flu (fevers, headaches, pain in the bones and joints); 
if patients have acute leukemia, they might experience easy bleeding and bruising, swelling or 
discomfort in the abdomen and swollen lymph nodes, especially in the neck or armpits. 
The examination by the physician will include the analysis of several different parameters, for 
example: 
 
• swelling of the lymph nodes and the liver, 
• blood composition, 
• antibody status, 
• coagulation rate, 
• x-ray of the thorax, the hand (bone status). 
• results of biomolecular and staining techniques.  
 
The physician might want to take a biopsy, removing some bone marrow from the patient’s 
hipbone. A hematologist will examine the swab under the microscope, studying the 
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morphology and cytochemistry [37, 38]. Surface antigen expression methods might be used to 
make leukemia cells visible under the microscope (figure 3.7).  
 
 
Fig. 3.7 Microscope image of a blood film from a patient with acute lymphoblastic 
leukemia (ALL). Leukemia cells are immunostained with the CD10 antigens. 
Application of different antigens gives information on the lymphoid leukemia 
deriving from the T-cell or B-cell lineage. 
 
The number of chromosomes is also studied, looking for diploidity, hypodiploidity and 
hyperdiploidity. Different methods might be used to further classify the sample like 
cytogenetics, interphase-FISH [39] and 24-color-FISH [40, 41]. 
 
  
Fig. 3.8 Interphase fluorescence in situ hybridisation (FISH) using probes for BCR 
and ABL genes. Translocation t(9;22)[BCR-ABL] becomes visible. 
 Left: Normal cell showing two red dots (two normal copies of the BCR gene)  and two yellow dots 
(two normal copies of the ABL gene). Right: Cell from a child with a certain acute lymphoblastic 
leukemia with translocation of chromosomes 9 and 22 (gene switching position from one 
chromosome to the other) [42].  
 
In this way, prognostically  unfavorable kinds of leukemia e.g. with translocation t(4;11) and 
t(9;22) can be detected. The aberration t(9;22) is rarely present in children with leukemia 
(2.2%) in contrast with hyperploidity (25 %) whit a  more favorable prognosis.  
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These bimolecular methods have gained importance during the last couple of years, especially 
within the detection of minimal residual disease (MRD). Examinations in the future will 
include the utilization of microarrays for the molecular diagnostic to gain more information 
on the subtype of the diagnosed leukemia [43]. 
 
 
3.3.2.3 Treatment and the significance of molecular differences of ALL subtypes 
 
An overall long-term event-free survival can only be achieved by using risk-adapted therapy 
that involves tailoring the intensity of the treatment to each patient’s risk of relapse. Pediatric 
leukemia for example is a heterogeneous disease consisting of several genetically distinct 
leukemia subtypes. B-cell leukemias can contain translocations (swapping of chromosome 
parts between different chromosomes)  like  t(9;22)[BCR-ABL]  (swapping of parts between 
chromosome 9 and 22), t(1;19)[E2A-PBX1], t(23;21)[TEL-AML1], rearrangements in the 
MLL gene on chromosome 11 or a hyperdiploid karyotype (i.e. > 50 chromosomes). The 
different genetic lesions in these leukemia subtypes have a great impact on the efficacy of 
cytotoxic drugs. Leukemias with t(1;19)[E2A-PBX1] for example respond poorly to 
conventional antimetabolite-based treatments. They have to be treated more intensively, this 
way reaching cure rates of about 80% [44].  
It is  difficult, time consuming and costly to accurate assign of a patient to a certain subgroup. 
Many hospitals do not have the facilities to perform all the tests, especially those in poorer 
countries. Even if the facilities are available, highly qualified personnel with much experience 
has to be found to do the analysis in the best possible way. Enhancing the prognostic criteria 
with results from microarray analysis will not only reduce the importance of this person-
bound quality criteria but give the medical examiners information that previously was not 
available. Examples would be the detection of novel cancer subgroups that might have to be 
treated in a different way and the understanding of genetic pathways playing a role in a 
certain cancer type.  
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3.4 DNA Biosensors 
3.4.1 Definition and Overview 
 
Biosensors rely on the direct spatial coupling of a selective biological component with a 
physical transducer [45, 46]. The analyte recognition is made possible through the use of the 
biological component while the transducer converts the resulting chemical or physical 
changes into an electrical signal, thus strongly influencing the sensitivity of the biosensor. 
The biological component can be composed of enzymes, antibodies, nucleic acids, receptors, 
microorganisms or even living cells. The most important classes of transducers are optical, 
electrochemical, piezoelectric and acoustic devices. The special advantage of biosensors is  
the  reversible interaction with the analyte so that the biosensor can be regenerated and used 
multiple times.  Many biosensors also characterize themselves as being easy to use, having 
low acquisition and operational costs, being small and of reducing the time needed for a 
measurement. 
DNA-biosensors are based on the specific hybridization between complimentary DNA single 
strands and make it thus possible to detect this bonding reaction. Single stranded  probe-
oligonucleotides are immobilized on the surface of the transducer, hence reacting with the 
complimentary target-sequences in the solution to be analyzed. Optical transducers are 
favored, many based on the exploitation of the phenomenon of surface plasmon resonance 
(SPR) and the evanescent field [47]. Also used in nucleic acid analytics are electrochemical 
transducers,  implemented in potentiometric, voltametric and amperometric detection systems. 
The probe-oligonucleotides can be immobilized on many different kinds of electrode 
materials. Many different methods for the creation of electrical signals for the detection of  
hybridization events have been implemented. Markers are either electro-active ligands that 
intercalate between the created double stranded DNA [48], or enzymes (e.g. peroxidases), that 
catalyze the reaction of electro-active substrates (e.g. H2O2) [49].  Immobilization of inosin-
substituted probe-oligonucleotides makes a labeling obsolete due to the detection of the 
guanine-signal after hybridization [50, 51]. 
Measurements without prior labeling can be accomplished by a variety of optical DNA-
biosensor-systems and piezoelectric methods like the quartz crystal microbalance (QCM) 
which registers the mass-change after hybridization on the surface of the sensor through a 
frequency change. This method is used less often as it exhibits a deficit in sensitivity 
compared to methods using other types of transducers.  An overview on the subject of DNA-
biosensors is given by Bier and Fürste [52] as well as by  Vercoutere and Akeson [53]. 
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3.4.2 DNA Microarray Technology 
3.4.2.1 Overview 
 
Huge advances have been made in the sector of the DNA-chip-technology during the last ten 
years. It has become a leading technology in nucleic acid analysis alongside the polymerase 
chain reaction (PCR) [54]. DNA-chips, also known as DNA microarrays, are miniaturized 
slides with known probe-oligonucleotides immobilized in high density on their surface as a 
grid (array). The probes are hybridized with complimentary, fluorophore labeled target-DNA 
from a sample-solution. Unbound target molecules are then removed by means of different 
washing steps. The bound fluorophores can be detected using a fluorescence scanner. The 
acquired signal pattern contains the information which sequences where present in the 
sample-solution.  
Depending on the target application, DNA microarrays can either be used for gene expression 
analysis or SNP (single nucleotide polymorphism) detection [55, 56]. DNA microarrays used 
for the former task are not only able to detect an expressed gene but, they can also quantify 
the expression. 
 
3.4.2.2 Spotted microarrays 
 
Probe-oligonucleotides can be immobilized on the surface of a slide by being spotted onto it. 
The resulting spots of oligonucleotides are round with an area without immobilized 
oligonucleotides between spots. This area can be used to query the background signal. 
 
Fig. 3.9 Image of a spotted microarray created at the ICB. Colors denote fluorescence 
intensities. The area of low intensity between spots can be used to query the 
background. 
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A dual gene expression analysis is made possible by the use of two sample-solutions, each 
labeled with a different fluorophore and applied onto one and the same chip. Signals of each 
sample can be detected by scanning the array using a wavelength according to the 
fluorophores used. Ratios of gene expression signals between both samples can be calculated, 
making it possible to compare them. This approach facilitates the data-analysis, as both 
samples are measured in one experiment and the effect of e.g. different hybridization 
efficiencies are taken into account.  As the rate of incorporation of the fluorophores into the 
oligonucleotides also depends on the type of fluorophore used, the two signal channels in this 
kind of experiment therefore also have to be scaled to be comparable. Further details on data 
preprocessing are discussed in the chemometrics chapter. 
 
 
 
3.4.2.3 Microarrays created by photolithography 
 
Oligonucleotides on microarrays produced by Affymetrix are not immobilized through 
spotting but created on the surface of the chip itself by photolithography. The oligonucleotide 
spots created by this process are square and reside tightly packed, so that there might not even 
be an area between spots that can be used to query the background signal (e.g. U133 
microarrays). The used technology was adapted from the semiconductor industry allowing 
these arrays to hold over half a million cells. This very high density makes it possible to 
create so called whole genome chips which can screen samples for gene expressions of more 
than 22000 different genes, each one sampled by several cells. The oligonucleotide probe 
synthesis occurs in parallel, adding the different nucleotides to growing chains simultaneously. 
A length of about 15-25 nucleotides (15-25 - mer) is used in the common commercial chips. 
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Fig. 3.10 Photolithographic steps in the creation of oligonucleotides directly on the 
surface of a microarray slide [source: Affymetrix, Inc.]. 
 
 
3.4.2.4 Medical Applications of DNA-biosensors 
 
DNA-biosensor-systems have been developed over the last ten years and have only been used 
for research purposes so far. DNA-biosensors are now at the brink of becoming true medical 
diagnostic devices [57, 58].  
In the last couple of years, high-density chips have increasingly been used to analyze the 
gene-expressions of several thousand genes in biological samples simultaneously in one 
experiment. The U133a chip of Affymetrix for example, can screen over 22000 genes. 
Researchers were thus able to analyze genetic pathways and to identify the role of genes faster 
and easier. A disadvantage of these chips lies in their cost. Thus, it is not feasible to perform a 
high-throughput screening of many samples. They are intended to help researchers and were 
not developed for medical applications, largely because as the interpretation of the data 
gained can be very tedious and difficult. 
Following the high-density chips are the so called low-density chips. These chips can detect 
the gene-expressions of only a few genes, these having been selected a priori with the 
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Fig. 3.11 : AmpliChip  
intention of obtaining certain information about the sample. It is therefore necessary to use 
high-density chips to design the low-density ones. A low-density chip normally costs less and 
can be evaluated using procedures adapted to this specific chip, thus making it possible to be 
used by non-experts. 
One example is the DNA-biosensor AmpliChip CYP450 
developed by Roche Diagnostics in cooperation with Affymetrix 
[59] which could become a landmark test case.  It is referred to 
by Roche as the company’s first microarray for clinical 
applications. It detects variations in two genes that affect the rate 
at which many drugs used, to treat cardiovascular diseases are 
metabolized. The information gained by using this device could 
help physicians to select the right drugs for their patients. This 
kind of tailor-made therapy is seen as the future of medical care 
by most pharmaceutical companies. 
Roche started marketing the AmpliChip CYP450 as an analyte-specific reagent (ASR) and a 
class 1 medical device which does not necessitate clinical demonstrations of effectiveness and 
safety. The Food and Drug Administration (FDA; Rockville, MD, USA) believes that the 
device has the potential of being used improperly, thus endangering patients through 
misdiagnosis, and should therefore be classified differently. As the FDA believes that 
genomic data and technologies have increasing importance in pharmaceutical research, a 
novel regulation of microarray devices for diagnostic purposes is expected to be put into 
action in the very near future. 
 
3.4.3 Affymetrix Microarrays 
 
3.4.3.1 Physical construction 
 
Affymetrix microarrays are created by using a photolithography process (see figure 3.10). The 
created spots on these microarrays are square and called cells by Affymetrix. The U133a [60] 
microarrays contain 712 x 712 cells, each cell composed of about 6 x 6 pixels in the raw data 
provided by the microarray scanner.  
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Fig. 3.12 U133 microarray from Affymetrix (A) [source: Affymetrix Inc.] and upper left 
corner of the image created by scanning the chip (B). Colors code the 
fluorescence intensity. Some cells are used to provide alignment help 
(checkerboard pattern at the boarder) and give information on the type of 
chip (GeneChip U133). 
 
 
The U133a microarray enables a researcher to quantify the gene expressions of 22285 genes. 
The gene expression of a certain gene is queried by several cells. These cells are called a 
probeset as they contain the probe oligonucleotides designed to hybridize with one certain 
gene. Most probesets are composed of 22 cells, 11 perfect match (PM) cells, and 11 mismatch 
(MM) cells [61].  
 
 
Fig. 3.13 Configuration of a probeset containing several cells. One probeset is  
  designed to query the gene expression of one certain gene. 
 
A perfect match cell is thus always paired with a mismatch cell. The oligonucleotides used in 
such a MM cell are the same as those in the PM cell, except for one mismatch in the center of 
the sequence. The mismatch base is the complimentary base of the corresponding Watson-
Cricks basepair (e.g. A interchanged with T, G interchanged with C).  Sequences in different 
probepairs differ from each other, designed to match the sequence of the target gene at 
different positions.  
Probeset 
Probepair 
Perfect Match Cell 
 
Mismatch Cell 
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Both cells of one probepair are always located besides each other on the microarray, different 
probepairs of one probeset are randomly spread throughout the chip to minimize the risk of 
loss of a complete probeset due to artifacts (see x- and y-pos in table 3.1). 
 
Tab. 3.1 Perfect match probe sequences for the gene 212019_at (Affymetrix 
identification code). 
 
  Name  X-pos Y-pos  Probesequence 
 212019_at 138 131 AACACTCAGCTTTTCGCAACATAAT 
 212019_at 124 179   CACTCAGCTTTTCGCAACATAATCC 
 212019_at 4 187 CAGCTTTTCGCAACATAATCCCAGC 
 212019_at 18 319 GCTTTTCGCAACATAATCCCAGCAC 
 212019_at 581 211 CTTTTCGCAACATAATCCCAGCACT 
 212019_at 426 333 GCACTTTGGAACGCTGGGTGGATTG 
 212019_at 98 669 TTTGGAACGCTGGGTGGATTGCTTG 
 212019_at 668 589 TGCAATGGGCCATGATCACGATCCT 
 212019_at 366 167 CAATGGGCCATGATCACGATCCTGC 
 212019_at 231 155 AATGGGCCATGATCACGATCCTGCA 
 212019_at 206 131 AACAGAGAGAGACAGTCCCTGGCCC 
 
 Notice the sliding character of the sequence selections. X- and Y-pos 
denote the position of the cell on the microarray. Mismatch sequences are 
the same as the PM sequences except for one mismatch in the exact center 
of the sequence. Corresponding MM cells have an Y-position increased 
by one.  
 
 
The Affymetrix rational for using PM and MM cells is as follows: the role of a perfect match 
cell is to provide the signal of the hybridization reaction of the probe oligonucleotides with 
the matching target oligonucleotides from the gene the sequence was designed for plus any 
additional signals from cross hybridizations with similar target oligonucleotides and 
background; the mismatch cell in contrast provides the signal of cross hybridizations and 
background only, therefore making it possible to calculate the signal of the selective 
hybridization.  
3.4.3.2 Calculation of gene expressions 
 
An experiment using Affymetrix microarrays yields many signals corresponding to all the 
cells (e.g. 506944 for the U133A chip).  These signals have to be translated into gene 
expression values. The procedure is as follows: 
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1. background correction of the entire microarray, 
2. application of a gene expression summary algorithm to gain a single value for each 
probeset, 
3. normalization of signals from different microarrays of one study. 
 
The MicroArray Suit (MAS) calculates probeset values using PM and MM cells of each 
probeset. Researchers have discussed the necessity of using MM cells, arguing that these cells 
may also detect a signal corresponding to specific binding  as well as non-specific binding and 
should therefore be omitted [62-64]. New gene expression summary algorithms have been 
created, achieving good reproducibility in signal calculation without using the MM cells (e.g. 
RMA [65, 66]). Some of these methods have also been used in chapter four. 
Different background correction and gene expression summary algorithms are discussed in 
the chemometrics chapter.  
 
 
3.5 Chemometrics 
 
3.5.1 Introduction 
 
Chemometrics is the application of mathematical, statistical, graphical or symbolic methods 
to design or select optimal measurement procedures and experiments and to maximize the 
information which can be extracted from data. Chemometric procedures can prove useful at 
any stage in an analysis, from the first conception of an experiment, to the extraction of all 
information [67-69].  
Pattern recognition approaches are used to identify similarities and regularities present in data. 
The most frequently used techniques have traditionally been those in the area of cluster 
analysis and classification. These methods help extract information out of data. Classification 
methods perform pattern matching and comparisons, helping to associate an unknown sample 
to known clusters of data. One of the primary goals of chemometrics is to reduce the number 
of dimensions needed to accurately portray the characteristics of a data set. A wide variety of 
methods are available to achieve this, either by selecting an important subset of the original 
variables (feature selection), or by creating a set of new composite variables, which are more 
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efficient than the original variables in describing the data (feature reduction). The creation of 
new variables can be approached in several ways; two of these are projection (e.g. principal 
component analysis) and mapping. 
It is critical for the data to be of good quality and to have been gathered using informative 
samples. Chemometrics should therefore be applied beforehand to design the experiment or 
measurement process. One important application is the analysis of how many experiments 
will be needed to obtain information that is statistically significant, and to optimize 
experimental parameters to improve the sensitivity and precision of analysis (e.g. simplex 
algorithm). Application fields include calibration techniques, resolution enhancement 
techniques (e.g. Fourier transformation, deconvolution), signal processing (e.g. dealing with 
noise), modelling and parameter estimation.  Data verification can be done by learning about 
the characteristics of the data like means, standard deviations, ranges, modes of distribution 
and other statistical measures. Process parameters for quality control can be estimated using 
this knowledge and possible outliers detected. 
 
3.5.2 The role of chemometrics in microarray experiments 
 
The use of microarray experiments has become popular due to its advantages for large-scale 
studies of gene expression and mutation analysis. This technology makes it possible to study 
complex systems in less time and to derive comprehensive information. Microarrays in 
combination with chemometrics and bioinformatics make it possible to tell, for instance, 
which genes behave differently in cancerous cells compared to healthy cells of the same tissue 
type. Researchers can hereby learn more about the processes in the cell and about factors that 
are involved in turning a healthy cell into a cancerous one. Moreover, the technique makes it 
possible to classify the cancer more precisely and to make a better decision on the treatment 
that should be applied.  
Many different steps are involved in the analysis of microarray data. At the beginning the 
relative gene expression level has to be obtained. Not only is noise inherent to the measured 
data, systematic errors can also be added during measurement and analysis alike. Errors must 
be detected and corrected before any downstream analysis, such as identification of 
differentially expressed genes and sample classification, can be performed [70]. The 
identification of noise components as well as systematic errors and artifacts is one major task 
of chemometrics. The data has to be pre-processed so that a comparison of different 
experiments becomes possible. The comparison itself also includes chemometric methods, for 
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example the application of t-tests, cluster analysis, principal component analysis and a whole 
range of other statistical calculations. Chemometrics provides the building blocks for the 
entire processing chain, starting from the processing of raw data up to the creation of models 
for the classification of samples and diagnosis. 
 
 
Fig. 3.14 Chemometrics provides means to process data and to create models for 
diagnosis. 
 
Different methods are explained in the chemometrics chapter, including basic techniques like 
PCA, clustering and cross-validation. Furthermore, this chapter includes explanations on 
different gene expression summary techniques that have been used to gain gene expression 
values for each probeset (see the Affymetrix technology chapter) as well as gene selection 
techniques that have been applied in order to select genes used for the classification of 
samples of different cancer subtypes. One major task of bioinformatics is to provide means 
for storing data reliably so that easy and fast access is possible. A databank system interfacing 
with Matlab was created for project management which is also explained in this chapter. 
Details on the application of methods for the analysis of a leukemia dataset can be found in 
chapter five. 
 
3.5.3 Pre-processing  
 
 
A common pre-processing step consists of mean centring, i.e. subtracting the mean over all 
samples for each variable: 
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A centred data cloud lies around the origin of the coordinate system (figure 3.15 II). 
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If the absolute values of the measured data are important, then centralisation should not be 
performed [71]. 
 
 
Fig. 3.15  (I) Raw data,    (II) Centered data,    (III) Standardised data. 
 
The  covariance, variance and standard deviation can easily be calculated by using two 
centred vectors: 
 Covariance:  
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One important aspect of pre-processing data is its standardisation.  
 
Standardisation: 
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The influence of arbitrary units (e.g. 1000m or 1 km) is eliminated through standardisation 
(figure 3.15 III ); all axis have the same scale. 
 
 
3.5.4 Cluster analysis – hierarchical clustering 
 
Cluster analysis can be defined as the unsupervised classification of similar objects into 
groups of which members and assignments are unknown a priori. The shape of a cluster can 
be characterised by its cluster-specific means, variance, and covariances that also have a 
geometrical interpretation [72, 73]. Objects in one subset will have similar properties.  The 
clustering algorithm defines by what kind of similarity measure objects are clustered together. 
Clustering is done by using an algorithm containing a distance calculation (Euclidean, 
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cityblock distance and other), and by using an updating part. Both parts can vary, depending 
on the used algorithm. The result of a cluster analysis can be displayed in a dendrogram. 
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Fig. 3.16  Exemplary dendrogram using Ward’s method on 13 objects. 
 
 
The dendrogram shows the distance between objects (index value where branches meet). 
Objects that lie near to each other (similarity measure) are connected through a branch at 
small index value. The used algorithm picks two objects that lie near to each other, connects 
them and continues working up to higher index values.  
It can be formulated as follows: 
 
1. Choose a distance measure. 
2. Calculate the distance matrix D for the dataset. 
3. Identify the smallest value dij in D (other than in the diagonal). 
4. Merge objects i and j. The so created new object is regarded as one new single entity. 
5. Update the distance between all other objects in D and the new entity. 
6. Return to number two and repeat until all objects are interconnected. 
 
The used Ward’s method calculates the distance between a new entity [AB], created through 
the merger of objects A and B, and an object C with the formula 
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It takes the number of samples in each of the united groups into account when updating the 
distance matrix, thus creating the new cluster center nearer to the group with more objects 
[74]. 
 
3.5.5 Principal component analysis 
 
3.5.5.1 Introduction 
 
Principal component analysis (PCA) seeks to maximize the variance information present in a 
data set in as few new dimensions as possible [75, 76]. Graphically, principal components 
analysis rotates the axes of the data to conform to axes which contain a maximum amount of 
variance information; this can be thought of as looking at the data from a different perspective 
in hyperspace. Principal component analysis is one of the most important multivariate data 
analysis techniques as it allows a good visualisation of underlying structures present in the 
data. It also allows for a dimensionality reduction, which can be used beneficially in 
subsequent tasks (classification, regression, and cluster analysis).  Figure 3.17 shows a plot of 
30 objects for which variables x1 and x2 were measured.  
 
Fig. 3.17  Plot of 30 objects with two variables (x1, x2) and first principal component y. 
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The axis y represents the first principal component (PC1). Of all one-dimensional subspaces 
(lines), this one covers best the variation of the data. Further principal components can be 
added, each successive component being orthogonal to the prior ones and covering as much as 
possible of the remaining variance. In figure 3.17 a second PC could be added thus reaching 
the maximal dimensionality possible for this data. Through the omission of insignificant low 
variance principal components a noise reduction is achieved. 
Principal components are linear combinations, i.e. a weighted sum of the original p measured 
variables [77]. If X is the data with n objects and p≤n variables, then a r ≤ p -dimensional 
linear subspace is looked for that covers the variance of the data the most. In order to achieve  
this, the eigenvectors and the eigenvalues of the covariance matrix of the data have to be 
determined. Normally, data will be pre-processed, undergoing centring and standardisation.  
 
3.5.5.2 Eigenvalues, eigenvectors 
 
Taken  X is a (n,n) symmetric matrix, then a v and λ exist so that 
 
X v = λ v  (1) 
 
λ are called eigenvalues, v eigenvectors. If (1) is written as Xv = λInv, the equivalent 
formulation (X - λIn) v = 0 is reached. In short: Av = 0 with A = X - λIn which is a linear 
equation. If A is not regular, then the only solution would be v = 0: 
  
 Ax = b ⇒ A-1Ax = A-1b ⇒ Inx = A-1b ⇒ x = A-1b ; 0 = A-1 0 
 
The null-vector is not seen as an eigenvector and is discarded. There is not only one 
eigenvector corresponding to an eigenvalue; they span a subspace (normally a line) because if 
a vector v solves equation (1), then also multiples αv that do so, too: 
 
X(αv) = αXv =αλv = λ (αv). 
 
Not every matrix has eigenvectors / eigenvalues, though symmetric (n,n)-matrices like 
covariance-, correlation- and distance-matrices that are often used in data-analysis always 
have n, not necessarily different, eigenvalues / eigenvectors forming  n „Eigen-pairs“ (λi , vi) 
that solve the equation: 
 
Xvi = λvi          
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It can also be written as a matrix-product, with the eigenvectors as columns of an eigenvector-
matrix and the eigenvalues constituting the diagonal of an eigenvalue-matrix: 
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or, in short:  
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The λi  are normally sorted to be in decreasing order λ1 ≥ λ2 ≥ ... ≥ λn. 
Different eigenvectors of symmetric matrices are orthogonal to each other. 
 
 
3.5.5.3 Calculations in Principal Component Analysis 
 
After pre-processing the (n, p)-data-matrix X, the (n-1)-1XTX-Matrix is calculated. If X were 
centred, then this newly calculated matrix would be the covariance matrix. If X were also 
standardised, it would be the correlation matrix. The main step in principal component 
analysis is the calculation of the p eigenvalues and eigenvectors of this matrix. The 
components of the eigenvectors contain the weights of the original variables needed for each 
principal component while the eigenvalues contain the variance it covers. Different 
algorithms can be used for the calculation of the eigenvalues / vectors [76]. 
 
 
 
3.5.6 Cross Validation 
 
The number of training observations usually is much larger than the number of features in a 
standard discriminant analysis. In microarray studies however,  the number of tissue samples 
measured is typically far smaller than the number of gene-expression detected. It becomes 
necessary to use cross validation to verify the credibility of a model, as the number of 
available samples is constricted. In cross validation samples are left out to create a training 
dataset. A model is created by using this subset and applied to the data points that were left 
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out. Several different methods for cross validation are available. In the leave-one-out (LOO) 
method each point of the dataset is left out successively to create the model.  Several data 
points can be left out, either in a Venetian-blind-, a block- or random-order-pattern. Cross 
validation prevents overfitting a created model to the dataset used, as it is validated using 
samples unknown to the model because they have been left out. It has to be taken into account 
that using all samples to select those features (genes) best suited for the construction of the 
model will introduce a prediction error. This selection bias can be evaded if the gene selection 
is performed in the cross validation process [78].  
 
3.5.7 Support Vector Machines (SVM) 
 
In a binary linear classification problem, a linear hyperplane which divides space into two 
regions corresponding to the two classes is looked for [79-81]. The class of an object i is 
defined by yi being +1 or -1.  The optimal hyperplane is orthogonal to the shortest line 
connecting the convex hulls of the two classes (see figure 3.18) and intersects it half-way 
between the two classes.  
 
 
 
w
 
Fig. 3.18 Binary linear classification using SVM. 
Diamonds are separated from circles by a hyperplane (solid line). Objects are classified using the 
weight vector w and the threshold b satisfying (w*x)+b ≥ 0 for all diamonds and (w*x)+b<0 for all 
circles.  
 
(w*x)+b < 0
(w*x)+b > 0
(w*x)+b = 0
yi = +1 
yi = -1 
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The hyperplane is defined by the weight vector w and the threshold b. These are defined so 
that   
 (w*x)+b ≥ 0 for all yi = +1, 
 (w*x)+b < 0 for all yi = -1. 
 
If w and b are scaled so that the distance between points closest to the hyperplane measures 
1/||w|| then all points with yi [ (w*xi)+b ] = 1 are called support vectors, all other objects 
having  yi [ (w*xi)+b ] > 1. The broadness of the separating region is then 2/||w||.  The aim is 
to maximize the minimal distance of the training data to the separating hyperplane [82, 83]. 
As data might not be perfectly separable, such a separating hyperplane may not always exist. 
It is thus necessary to use methods that deal with misclassification. A slack variable ξi  is 
introduced so that  
 
 (w*x)+b ≥ +1-ξi  for all yi = +1, 
 (w*x)+b ≤ -1+ξi for all yi = -1. 
   ξi≥0. 
 
There are three possibilities: 
 
 ξi = 0 : xi was classified correctly and lies at the border or outside of the 
separating region. 
 0<ξi<1 : xi was classified correctly but lies inside of the separating region. 
 ξi ≥ 1 : xi was classified incorrectly. 
 
Note that all samples with ξi ≠ 0 are considered as margin errors. 
The aim is to reduce the rate of misclassification and to maximize the separating region. The 
new optimization of  yi [ (w*xi)+b ]  ≥ 1-ξi  is 
 
 

 + ∑
=
1
1
2
2
1min
i
k
iw
ξCw  
 
The trade-off parameter C penalizes margin errors for the training data. It can be optimized 
e.g. through cross-validation techniques. 
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3.5.8 Gene selection Methods 
 
 
3.5.8.1 Gene shaving 
 
Gene shaving extracts coherent, typically small clusters of genes that vary as much as possible 
across samples [84]. The shaving procedure is as follows (see also figure 3.19): 
 
1. Use the entire expression matrix X, row centred to have zero mean. 
2. Calculate the first principal component. 
3. Discard a certain percentage of genes with the smallest absolute inner-product with the 
principal component. 
4. Repeat steps two and three until only one gene remains. A nested sequence of clusters  
SN § Sk § Sk1 § Sk2 § S1 where Sk denotes a cluster of k genes is created. The optimal 
cluster size kˆ is calculated using the gap statistic described in [84]. 
5. Orthogonalize each row of X with respect to 
kS
x
ˆ
, the average gene in kS ˆ  to promote the 
discovery of  different (uncorrelated) clusters in further iterations of the procedure. 
6. Steps 1-5 are repeated with the orthogonalized data to find the second optimal cluster. 
This process is continued until a maximum of M clusters is found. The value of M is 
chosen a priori. 
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Fig. 3.19 Schematic of the gene shaving process (source: [84] ). 
 
3.5.8.2 Significance analysis of microarrays (SAM) 
 
Coherent patterns of gene expression can be found by using cluster analysis. This method 
does not provide much information on the statistical significance of the selection of genes. 
Conventional t-tests are often used  but have the drawback that, applied to microarray data 
with thousands of genes, several genes will be identified by chance even when using p=0.01. 
This led to the development of SAM by Virginia Goss Tusher, Robert Tibshirani and Gilbert 
Chu [85]. Genes with statistically significant changes in expression are selected with SAM by 
assimilation of a set of gene-specific t-tests. A score is assigned to each gene based on the 
change in gene expression relative to the standard deviation of repeated measurements for that 
gene. A gene is rated as potentially significant if its score is higher than a threshold. The false 
discovery rate is identified by analyzing permutations of the measurements. Although the 
signal to noise ratio decreases with decreasing gene expression, the fluctuations for a specific 
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level of expressions are gene specific. These fluctuations are assessed with the relative 
difference d(i): 
0)(
)()(
)(
sis
ixixid BA +
−=  
with )(ixA  and )(ixB  defined as the average levels of expression for gene (i) in groups A and 
B respectively, and s(i) defined as the standard deviation of repeated expression 
measurements.  To ensure that the variance of d(i) is independent of gene expression, a small 
positive constant s0 is added to the denominator (see [85] page 5117). 
Significant changes in gene expression are found by ranking genes by the magnitude of their 
d(i) values, so that d(1)>d(2)>…>d(i). Relative differences dp(i) are also calculated for 
permutations of measurements balanced for different subgroups, and genes again ranked in 
such way  that dp(1)>dp(2)>…>dp(i). The expected relative difference dE(i) is then defined as 
the average over all Np balanced permutations: ∑= p pE Npidid /)()( . Changes in expression 
which might be significant can be identified using a scatter plot of the observed relative 
difference d(i) vs. the expected relative difference dE(i) as seen in figure 3.20. 
 
 
 
Fig. 3.20 Scatter plot of the observed relative difference d(i) vs. the expected relative 
difference dE(i). Genes with significant changes in expression are highlighted 
as gray squares. The threshold (dashed lines) was set to a fold change of three. 
TheE2A-PBX1 and T-ALL sample subgroups from the leukemia dataset [86] 
were compared. 
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3.5.8.3  Predication Analysis of Microarrays (PAM) 
 
Class prediction is based on an enhancement of the simple nearest prototype (centroid) 
classifier which works as follows: for each class a training-set nearest-centroid (average 
expression of each gene in the subgroup) is computed and the overall gene expression 
centroid subtracted. The resulting values are differences from the overall centroid. The 
squared distance from the gene expression profile of every test sample to each of the class 
centroids is computed. The predicted class is the one whose centroid is closest to the 
expression profile of the test sample.  This method uses all genes in the dataset. A 
modification of this nearest-centroid method, called nearest shrunken centroid was developed 
by Robert Tibshirani, Trevor Hastie, Balasubramanian  Narasimhan and Gilbert Chu, which 
only uses a subset of the genes [87, 88].   
Let xij be the expression for genes i=1,2, … p and samples j= 1, 2, …. n. Classes are 1, 2, … 
K and Ck are indices of the nk samples in class k. The ith component of the centroid for class k 
is ∑ ∈= kCj kijik nxx / , the mean expression value in class k for gene i;  the ith component of 
the overall centroid is ∑ == nj iji nxx 1 / [87]. The class centroids are shrunken towards the 
overall centroids after having been standardized by the within-class standard deviation for 
each gene. Let 
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with si the pooled within-class standard deviation for gene i , nnm kk /1/1 +=  and s0 be a 
positive constant. The method shrinks each dik toward zero, giving d’ik and yielding shrunken 
centroids '0
' )( ikikiik dssmxx ++= .  Each dik is reduced by an amount ∆ in absolute value and 
is set to zero if its absolute value is less than zero. It is defined by  +∆−= ))((sign' ikikik ddd  
with + meaning positive part (t+ = t if t>0 and zero otherwise). The threshold parameter ∆ is 
selected through cross validation. 
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Fig. 3.21 Shrunken differences d’ik for 40 genes having at least one nonzero difference. 
These genes are the PAM selection for the discrimination of E2A-BPX1 and 
T-ALL samples of the leukemia dataset [86]. 
 
 
 
3.5.8.4 Fisher’s Ratio  
 
Let { }111 1,..., lxx=1X  and { }221 2,..., lxx=2X  be samples from two different classes. Fisher’s 
linear discriminant is given by the weight vector w which maximizes 
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The rational behind maximizing J(w) is to find a direction which maximizes the projected 
class means (the nominator) while minimizing the class variance in this direction (the 
denominator). The weight vector w can thus be used to select those variables contributing the 
most in separating the two classes, making it possible to choose a  subset of variables best 
suited for class discrimination. 
 
 
3.5.9 Gene expression summary algorithms 
 
3.5.9.1 Affymetrix MicroArraySuit (MAS) 5.0 algorithm 
 
A signal is calculated by subtraction of an ideal mismatch IM value from the PM value. This 
IM value is a corrected MM value to assure that the resulting difference is larger than zero. 
The calculated signals after subtraction for each probepair are used to calculate the gene 
expression value for that probeset. This is done by means of a biweight estimator to provide a 
robust mean:  signal = Tukey Biweight. The exact algorithm is described in the Statistical 
Algorithm Description Document [89], page 3.  Further on, a detection call is calculated, 
giving the information of whether a transcript of a particular gene was deemed present or 
absent in an experiment. First, a discrimination score Ri, a measurement of the difference 
between the PM and MM intensities, is calculated for the ith probe pair: 
 
ii
ii
i MMPM
MMPMR +
−=  
 
If the median( Ri ) is greater than a threshold τ (default τ = 0.015), the hypothesis that PM and 
MM are equally hybridizing to the sample can be rejected. Wilcoxon’s rank test is used to 
calculate a significance or p-value. This p-value is then compared with preset significance 
levels to make a call. 
 
0 0.02 0.04 0.06 0.08 0.1
Present Absent Marginal 
 
 
Fig. 3.22 Comparison of the calculated p-value with preset margins to make a call.  
 
p-value 
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3.5.9.2 MAS, perfect match only 
 
The same steps are used as in the MAS approach, except for the subtraction of an IM value 
from the PM one. MM cells are thus not used at all. 
 
 
3.5.9.3 Li – Wong  Model 
 
For each probeset n, Li and Wong’s measure [90, 91] is defined as the maximum likelihood 
estimate of the Θi, i = 1,...,I  obtained from fitting 
 
 PMij – MMij = Θi Φj  + εij  
 
with   j number of  probepair, 
 i number of sample, 
 Φj  representing probe-specific affinities and 
 εij assumed to be independent normally distributed errors. 
 
The estimation procedure includes rules for outlier removal. 
 
 
3.5.9.4 RMA  Model 
 
The robust mutli-array average (RMA) is a summary measure of background-adjusted, 
normalized and log-transformed PM values. 
 
For probeset n, fit a linear additive model 
 
 ijjiij baBGPM ε++=− )(log2  
 
with  i: label of chip, 
 j: label of probe, 
 BG: background 
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 εij: errors.  
 ai:  gives the expression for probe n on array i.  
 
RMA estimates ai for chip i using a robust method, such as median polish (fit iteratively, 
successively romoving row and column medians, and accumulating the terms, until the 
process stabilizes). 
 
 
 
4 Method development 
 
4.1 Databases 
4.1.1 Introduction 
 
Storing data in file systems is accompanied by several disadvantages: 
 
• Possible data redundancy and inconsistency. Data is often stored in many different file 
formats and data structures, especially if several different persons are working on the 
same project. 
• Concurrent access of the data is made difficult as new routines to access the 
information might  be needed for each new task.  Users might not be able to access or 
store files as these are used by others at the same time. 
• Supplementing certain information is difficult as many different files (with different 
formats) might have to be changed. 
• Integrity problems. The meaning of the data and vocabulary used in one file (created 
by a certain scientist) might not be used the same way by someone else creating a 
different file [92].    
 
 
In databases, data is stored as tables. The database management system (DBMS) interacts 
with these tables on the behalf of the researcher, making it possible to sort, search and fetch 
subsets of the data in the tables.  The strength of DBMSs: 
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• Provide fast access to selected parts of large databases. 
• Powerful ways to summarize and cross-link information in databases. 
• Concurrent access from multiple users running on multiple hosts while enforcing 
security on access to specific data. 
• Ability to act as a server to a wide range of clients,  independent of their geographical 
location. 
 
The user applies a Data Manipulation Language (DML) to interact with the database.  The 
most widely used nonprocedural language is the Structures Query Language (SQL). 
For a nonprocedural language the user specifies what data is required without specifying how 
to get that data. 
 
4.1.2 Microarray Data Management System 
  
Microarray data obtained in large studies can reach a size of several gigabytes. The data from 
the microarray measurement itself is usually stored on file servers so that they can be easily 
accessed by different users. In addition, the following corresponding clinical information for 
each sample has to be stored: 
 
• patient age, 
• patient prognosis, 
• classification of illness (e.g. ALL-lymphoma), 
• illness information (e.g. tumor stage), 
• sample processing information, 
• name of technician making the measurement, 
• data gained by other methods (e.g. pathological information gained by 
immunostaining, cytogenetics), 
• filenames of  the raw data, preprocessed data etc., 
• data gained in the microarray-data processing. 
 
 
The Microarray Data Management System (MDMS) was designed to provide easy access to 
the data without requiring the user to know the exact name of the data files or their  location 
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on the fileserver.  Interaction in Matlab® [78] with the data was achieved using MySQL [72]. 
It is available under the GNU General Public License (GPL) and was in use more than four 
million times world wide by the end of the year 2003. The used MySQL interface in Matlab 
was written by Robert Almgren from the University of Toronto [93].  The MDMS structure is 
depicted in figure 4.1. 
 
 
 
Fig. 4.1  Structure of the Microarray Data Management System. 
 
 
Routines were written in Matlab to easily process the data, starting from the raw data files. 
Different processing steps could be applied to certain files by executing routines provided 
with specific database selection criteria.  
The Minimum Information About a Microarray Experiment (MIAME) project [94], approved 
by the Microarray Gene Expression Database group (MGED) in a Stanford University 
meeting in 2001, deals with the concept of a clear and structured storage of information. A 
similar mode of operation has been adopted by the macromolecular structure community (see, 
for example http://msd.ebi.ac.uk) where most journals require submission of a well-defined 
minimum of raw data associated with publications. The corner stones of MIAME are: 
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1. The recorded information about each experiment should be sufficient to interpret the 
experiment and should be detailed enough to enable comparisons to similar 
experiments.  
2. The information should be structured in a way that enables useful querying as well as 
automated data analysis and mining. 
 
The developed microarray data management system has been developed in concordance with 
these corner stones. 
 
 
4.2 Analysis of the raw data provided by the scanner 
 
A part of a raw microarray image provided by the scanner is seen if figure 4.2. The images 
often are skewed, i.e. the borders of the actual array in the center of the image form a 
parallelogram. One example of the left, vertical array boundary is shown in figure 4.2. The 
shift in position of the boundary to the left measures 5 pixels in this example. 
 
Fig. 4.2 Part of the image of a U133A chip provided by the scanner 
 
 The left border of the microarray is shown. The microarray itself is positioned in the center of the 
chip (and thus in the center of the image). Many cells merge together in this view, creating the 
illusion of there only being a few cells along the height of the image. The image is skewed, the 
microarray borders do  not form a rectangle. 
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The exact position of a cell in the microarray does not coincide with discrete pixel 
coordinates. The exact coordinates of all the features have to be linearly interpolated using the 
determined pixel-level coordinates of the corner features. If the coordinates of the corner 
features are determined incorrectly, erroneous cell values will be extracted from the image 
[90, 95]. A tool for the exact localization of the corner feature coordinates was developed in 
this work. The localization of the microarray boarders is possible by analysis of the first 
deviation of horizontal and vertical intensity profiles. An accurate detection of the position of 
the corner features is done within ±1 pixel. The interpolation leads to a certain amount of 
signal overlay in the border values of neighboring features. Further, it should be noted that the 
lithographic process used for the synthesis of the oligonucleotides also infers uncertainties 
concerning the exact sequence of the oligonucleotides at the border of each feature. As diffuse 
light shines onto the border of a neighboring feature that lies besides a cell that is illuminated, 
sequences might be created in this region which have not been explicitly designed.  
 
 
 
 
 
 
Fig. 4.3 Photolithographic process in which oligonucleotides are created on the 
surface of the microarray. 
  
Oligonucleotides are created on the surface nucleotide after nucleotide: light eliminates protecting 
groups at the end of the oligonucleotides, making it possible to extend those molecules with 
another nucleotide. As light also partially shines onto neighboring cells, oligonucleotides will be 
created in the border regions which have not been explicitly designed.  
 
 
 
 
Base 1 
 
Base 2 
 
Base 1+2 
Unprotection After addition of the next nucleotide. Mask
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This means that the border values of each feature must not be used to calculate the overall 
signal of a cell. It is therefore necessary to discard the outer perimeter of each feature; an 
average of 16-24 pixels from the center are used (from a total of ~36 pixel).  The values of the 
remaining pixels also differ from one another. As can be seen in figure 4.4, pixel intensity 
value are not homogenous.  
 
Fig. 4.4 Outtake of a raw U133A microarray image provided by the scanner 
Each cell has a dimension of about 6x6 pixels; pixel intensities in a cell deviate from one another. 
Z-axis values denote fluorescence intensities. 
 
The signals of these central pixels can deviate up to 30% from the mean fluorescence intensity 
of that feature (figure 4.5). 
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Fig. 4.5 Boxplot of standard deviations of signal intensities in features from three 
different measurements.  
 
Each feature consists of  16-24 pixels. The signal intensities of these pixels can deviate up to 30% 
in one feature. Measurements of three different studies were analyzed: (1) CD4 lymphocytes from 
peripheral blood dataset [96] , (2) Ross pediatric leukemia dataset [86], (3) proprietary dataset 
[97].  
 
The primary source of these in-cell signal deviations is thought to be the different 
hybridization efficiencies at different locations [98-100] . Heterogeneous hybridization can be 
improved by creating conditions enhancing the surface-near diffusion. The surface density of 
the probes also influences the ability of the immobilized probes to capture solution-phase 
targets. Bondage kinetics is lower in regions with high probe density, probably due to 
variations in target capture capabilities [98-100]. The surface density may also depend on the 
spatial positioning of the oligonucleotide (e.g. upright or parallel to the surface) and also on 
its geometrical conformation (e.g. linear or creating loops). 
 
4.3 Artifact detection 
 
Features on a U133 microarray from Affymetrix are of the size of 18 µm. With over half a 
million features packed side by side in one microarray, the detection of artifacts becomes 
essential. Artifacts can appear in very different shapes and sizes. The microarray analysis 
software of Affymetrix provides a tool for the user to mask cells per hand. As a detection of 
artifacts in raw signal images is often impossible and a selection by hand also likely to be 
imperfect due to the exhaustiveness of checking an area of 712 x 712 cells, an automatic 
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scheme for artifact detection was developed. This algorithm uses multiple microarrays to 
create a median-chip-image and a thresholding scheme to detect artifacts which become 
detectable as deviations from the median signal. 
 
4.3.1 Medianchip images for artifact detection. 
 
It is possible to detect artifacts reliably using several microarray chips. First a medianchip is 
created, by calculating the median of the signal of same cells over all preprocessed chips. The 
preprocessing takes account of background and scaling differences. 
 
 
Fig 4.6 Creation of a medianchip from several microarrays. The median of the signal 
of same cells over all preprocessed chips is calculated. 
 
 
This medianchip is used to calculate a ratiochip by dividing the signal of each cell from  a 
specific microarray by the value of the same cell on the medianchip and taking the logarithm. 
As cells with the same probe oligonucleotides are compared, only those cells which are 
differentially expressed should show a great deviation from the median. The rest of the cell 
values on the ratiochip should be more or less the same. The thresholding algorithm was 
tuned so that a small group of neighboring, differentially expressed cells is not masked but 
only larger areas of anomalies are, as seen in figure 4.7. 
 
 
Median
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A1 A2 
 
 
B1 B2 
 
Fig. 4.7 Artifacts on U133a microarrays seen in a raw image (A1) and ratio images. 
A1: raw image as taken by the CCD camera; A2 – B2: good recognition of artifacts in ratio images. 
Ratio images show log(cell signal/median signal). The horizontal pattern in B1 is a product of 
downscaling the image for presentation and not present in the data. Different colors denote different 
fluorescence signal values. 
 
 
 
 
 
 
4.3.2 Artifact detection algorithm 
 
A lowpass filter is applied on the ratioimage, eliminating all small features that might 
represent differentially expressed cells [101-103]. The lowpass filter was implemented using a 
moving window 9 by 9 pixel median filter. Its size was optimized to smooth out differentially 
expressed cells but not known artifacts. This lowpass image (see figure 4.8 B) is then 
converted into a mask image by thresholding (figure 4.8 C). The level of the threshold is 
calculated using a larger area of the image, thus gaining information of the overall signal in 
this image. This is done with another, larger moving window used to calculate the median 
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signal in that area. The chosen threshold is then chosen relative to this signal level, thus taking 
account of signal slopes etc. 
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Fig. 4.8 Process of masking. Left: ratioimage; Center: thresholded image using a 
lowpass filter; Right: masked areas. Shown measurement is JD-ALD416, E2A-
PBX1 subgroup of the Ross pediatric leukemia dataset [86]. It is further 
analysed in the leukemia data analysis chapter. 
 
 
The MAS software of Affymetrix also masks some cells using pixel-statistics, i.e. pixel 
information  for a cell in the raw images provided by the scanner [95].  
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Fig. 4.9 Position of cells masked by the MAS software in the measurement shown in 
figure 4.8A . As the masking is done using the pixel statistic of each cell, larger 
artifacts are neither recognized nor masked. 
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The larger artifacts are not recognized by this MAS masking algorithm. In this sample, 23500 
cells where masked by the newly developed thresholding algorithm. 45% of all probesets had 
at least one probepair in the masked areas, 80% of these having one probepair, 20% having 
two probepairs in this region. The distributions of cells masked by the MAS software seemed 
to be random in all analyzed studies (e.g. [86, 96, 97, 104, 105] ). Figure 4.10 displays the 
position of all masked cells in the entire Ross pediatric leukemia dataset [86]. 
 
 
 
Fig. 4.10 Homogeneous distribution of cells flagged as outliers by the MAS software in 
all the U133A microarrays in the Ross pediatric leukemia dataset. 
 
 
The masking algorithm is capable of recognizing and masking all kinds of artifacts commonly 
seen in U133 microarrays. Some artifacts in the pediatric leukemia dataset [86] and their 
masking  can be seen in figure 4.12.  
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Artifacts can also often be recognized in the scatter plots of a measurement against the 
medianchip. Figure 4.11A shows a plot of cell intensities of a sample without artifacts against 
the cell intensities of the medianchip. Figure 4.11B on the other hand, shows the scatter plot 
of the sample shown in figure 4.8A.  
 
 
A B 
 
Fig. 4.11 Scatter plots of  a sample without artifacts (A) and with artifacts (B , sample as 
shown in figure 4.8A) against the medianchip. The presence of an artifact can 
be seen in the abnormal form of the plot (red datapoints). 
 
 
The number of artifacts in one microarray varied from no artifacts at all to such an amount of 
artifacts that a measurements had to be discarded. All the analyzed studies [86, 96, 97, 104, 
105]  had a similar global amount of artifacts; no study was clearly worse then the others.  
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Fig. 4.12 Ratioimages with masked artifacts (defined by red contours). A close-up of 
the artifacts is visible at the right. All images were taken from the pediatric 
leukemia dataset [86]. Colors denote signal values, color range of right side 
images was chosen for best artifact display. 
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4.4 Background correction 
 
4.4.1 Background in Affymetrix Microarrays 
 
The background in a microarray measurement consists of signal intensity caused by non 
specific binding and autofluorescence of the array surface. Since probes are so densely packed 
on Affymetrix microarrays, there are no regions on the chip designed to query the background 
signal. Further, signals on U133 microarrays are not distributed in a homogeneous way:  
horizontal stripes exist on the chip containing high-intensity cells, brighter than their 
surroundings. 
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Fig. 4.13 Median and minimum intensities distributed along the horizontal (A1) and 
vertical (B2) profile of an exemplary U133 microarray.  
  
 Regions with different intensities can be seen along the vertical profiles, also when regarding the 
minimum intensities along the vertical profiles (B2). 
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Without regions on the chip designed to measure the background signal, Affymetrix uses the 
lowest 2% of the signals in zones of the chip to define it. It is assumed that there are always 
cells not showing any signal except for the background, as they cannot hybridize with 
complimentary target oligonucleotides which are lacking in the sample solution. 
 
Affymetrix calculates the background as follows: 
 
• The array is split up into K rectangular zones ZK (k=1,…,K, default K=16); 
• Control cells and masked cells are not used in the calculation. 
• The cells are ranked and the lowest 2% are chosen as the background  for that zone. 
 
Distances are then computed for each cell to the center of each zone. The background of this 
cell is computed using the zone-backgrounds and the distances to the centers of these zones as 
a weighting function. Weights are calculated based on the reciprocal of a constant plus the 
square of the distance to all the zone centers. 
As can be seen in figure 4.13, it is vital to use zones that are large enough not to be influenced 
by the stripe pattern of the chips. Using large zones on the other hand limits how accurate the 
background can be sampled. 
 
4.4.2 Background estimation using the checkerboard pattern 
 
A different method for the calculation of the background is the use of the checkerboard 
pattern at the border of the chip (see chapter 3.4.3.1).  The cells of the checkerboard with low 
signals are a good representation of the background as there is a linear correlation between the 
median signal of these cells and the mean signal of the lowest 2% in the microarray as can be 
seen in figure 4.14.  
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Fig. 4.14  Linear dependency between the median signal of checkerboard cells and the 
mean signal of the lowest 2% in the microarray using several hundred chips of 
the type U133a of one study [97]. 
 
 
The ratio between the lowest 2% and the checkerboard signal can be easily obtained by 
measuring the lowest 2% at a few, large areas in the microarray and comparing it with the 
checkerboard signals. Using large areas eliminates any local effects. The checkerboard data 
points are a good estimate for the background after adaptation to the ratio (1:2 in this 
example) as seen in figure 4.15. A horizontal view was chosen, as the irregular distribution 
seen in figure 4.13 B2 is not perceived when dealing with columns (figure 4.13 A2).  
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Fig. 4.15  Lowest signals in columns (gray dots) and estimated background using the 
checkerboard method (black stars). 
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These data points can be used for interpolation of the background in the microarray, the 
advantage of this method being that the background is sampled at many more points than with 
the zone approach described earlier.   
As can be seen in figure 4.16, the ratios between the mean lowest 2% signals and the median 
signals (measured at different locations of a chip and the entire chip) yield similar values in 
all analyzed U133A microarrays (raw, unscaled data).  
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Fig. 4.16 Mean lowest 2% signal against the mean overall signal of several 
microarrays from four different studies. 
  
The different studies are: Affymetrix spike-in dataset (gray dots) [105], Ross pediatric leukemia 
dataset (black dots) [86], PGA Human CD4+ Lymphocytes (gray pyramids) [96] and a PGA 
Human Muscle Obese dataset [104]. Shown are the signals gathered using all cells (excluding 
Affymetrix control cells). 
 
 
Raw signals of microarrays from one study can have very different scaling, independent of 
scanner-settings. Cells that should not show any specific hybridization, e.g. cells containing 
targets for probes not included in the sample-solution) and are therefore considered as the 
signal background seem also to be subjected to this scaling factor.   
One possible source of different scaling might be the amount of probe-molecules in the 
sample-solution used for analysis. Capture of the complementary target is modeled by Chan, 
Graves and McKenzie [98] using two different mechanisms by which targets can hybridize 
with the complementary probes:  
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1. direct hybridization from the solution, 
2. nonspecific adsorption followed by surface diffusion to the probe.   
 
If the surface diffusion is taken into account, this model might explain a correlation between 
low-level background cell signals and overall signal intensity. 
 
4.4.3 Interpolation using the Auto-leveling Method  (ALM) 
 
An iterative fitting process discards points above a threshold and fits the remaining points 
with a plane. First, a least squares plane is fitted to the anchor points. If there are fewer points 
above this plane than below it, they are classified as being outliers and are discarded. This 
process is repeated until the amount of anchor points above the plane is larger than or equal to 
those below the plane. The resulting plane which automatically reaches the level of the 
majority of the data points in this iterative procedure represents the fitted background [106]. 
 
 
4.4.4 Thin-plate interpolation 
 
4.4.4.1 Theory 
 
The interpolation of the background defined by the checkerboard cells is done by using a thin-
plate spline. Used correctly, this function will fit the data like a thin plate of metal, able to 
twist a little bit without overfitting the data. The spline function has to approximate many 
different data points in space that also contain noise [107, 108].  
The surface can be defined by 
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with  
φ(x) a fixed radially symmetric, basic function, 
λn a set of N weights corresponding to the N centers, 
p(x) a polynomial of degree k. 
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A datapoint  fn can be decomposed into a signal component yn and a noise component εn , i.e. 
 
nnn yf ε+= , 
 
with the εn being independent and normally distributed. Interpolation involves minimizing a 
penalty function.  
The penalty function in thin plate splines is 
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As it is not wanted to interpolate noisy data points exactly, a tradeoff is sought, minimizing 
the penalty function against the mean square error in fitting the data. This leads to the 
regularized least-squares problem: 
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x  
 
The parameter v attunes the tradeoff between goodness of fit and smoothness. The problem 
now is to find the best value for v.  Exact solutions to the minimization problem can be found 
in [109]. The selection procedure for v is described further down. 
 
 
 
4.4.4.2 Background subtraction 
 
Background data can be fitted best with a nonlinear method. Using a linear background 
produces fits as seen in figure 4.17. 
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Fig. 4.17 Linear fit to noisy data points. 
 
A good fit or overfitting is achieved depending on the parameter v.  
 
Fig. 4.18 Nonlinear fit to noisy data using a thin-plate spline. 
 
As the checkerboard data is noisy, setting the thin-plate spline too soft can have immense 
overfitting effects as seen in figure 4.19. 
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Fig. 4.19 Nonlinear fit to noisy data using a very soft thin-plate spline resulting in 
overfitting.   
 A clear overfitting of the soft thin-plate spline is visible. The peak of the thin-plate spline in 
the back-left corner is created by the influence of a large amount of datapoints that are 
elevated in relation to the surrounding points. Sparse outliers as seen in the back-right 
corner only lead to overfitting effects once the thin-plate spline is set much softer. It is 
therefore not possible to counter the overfitting effect by eliminating some of the visible 
outliers at this stage. 
 
Although the smoothness parameter can be chosen using the technique of cross-validation to 
measure the predictive error of a surface [108], an approach using replicate microarray data 
was chosen. The Latin Square dataset from Affymetrix [105] was used to evaluate the 
goodness of fit of the calculated background spline. There are 42 very homogeneous replicate 
measurements of a complex human sample in the dataset, spiked with certain target 
oligonucleotides. These spike-in cells were discarded and the measurements were overlaid 
with an arcustangens function, creating a step in the microarray data image that should be 
fitted. 
 
0 100 200 300 400 500 600 700
100
150
200
 
Fig. 4.20 Profile of the simulated uneven background. 
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This function was added to the measurements in different orientations and in different 
amplitudes. The form of the step function as well as its amplitude range was selected to be as 
similar as possible to those steps seen in real-life measurements. The calculated fit was then 
subtracted from the data. The deviation between same cells of different measurements was 
compared to the unprocessed data and thus used to evaluate the goodness of fit.  It was 
calculated as a measure of the standard deviation between same cells on all microarrays.  
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with  x,y the horizontal and vertical dimension of the array, 
 cellxy a vector containing the values of all cells at position x,y, 
 n the number of microarrays in the study (and the length of the vector cellxy). 
 
 
Using only checkerboard cells for a thin-plate nonlinear interpolation shows bad performance, 
a clear indication of a bad fit. 
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Fig. 4.21 Comparison of goodness of fit of background interpolation methods.  
 Measurement of deviation between replicate measurements when no background was 
subtracted (Raw), interpolation using the auto-leveling method (ALM) or a nonlinear 
thin-plate spline (nonlinear). Only checkerboard data points were used for 
interpolation.  
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Here, the strength of the thin-plate spline is also its weakness: it is only defined by border 
cells, its center is free to be stretched as governed by the smoothing factor.  
 
 
 
 
Fig. 4.22 Stretching of a thin-plate spline defined by border anchor points. 
Large steps in the data to be fitted result in a stretching of the thin-plate spline, 
resulting in a bad fit. 
 
 
 
This clearly shows that, at least when dealing with larger steps, anchor points within the 
microarray are needed to compensate for this overstretching. These anchor points were 
selected with a zone-method as used by Affymetrix. The chip is divided into zones and the 
mean of the lowest 2% is calculated for this zone. This value is seen as located in the center of 
the zone. The addition of these anchor points (25 used by default, corresponding to 5 x 5 
zones) greatly improves the performance of the nonlinear method. 
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Fig. 4.23 Good performance of the nonlinear, thin-plate spline interpolation.  
The thin-plate spline interpolation (Nonlinear), using anchor points at the border of 
the microarray (checkerboard) as well as in the spotted area, fits the background the 
best compared with unprocessed data (Raw) and the auto-leveling method (ALM). 
 
 
The optimization of the parameter v, achieved by this method using the dataset changed by 
the addition of the tanh-background, lead to a setting of v =10-5.  
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Fig. 4.24 Best results when fitting the surface using the thin-plate spline are achieved 
when the smoothing parameter is set to 10-5.  Higher values make the spline 
too inflexible, lower ones too flexible, leading to overfitting. 
 
This is the optimal value for background interpolation of the used dataset. The value selected 
using the tanh-changed measurements is a good choice for most measurements, as the dataset 
contained a non-uniform background with an intensity difference of a magnitude often seen in 
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U133 measurements. Application of this method on  measurements from different studies [86, 
96, 97, 104] showed its performance to be as expected. 
  
 
4.4.5 Application of a scaling factor 
 
Different measurements are scaled before comparison. These factors compensate for different 
signal ranges due to different amounts of sample RNA, different gain settings and 
hybridization efficiencies. The necessity of scaling can be seen in the effect on the histogram 
of the measurements [110]. As most genes are not differentially expressed in different tissues, 
the overall signal distribution in different experiments should be the same. This is achieved 
through scaling as seen in figure 4.25. 
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Fig. 4.25 Histograms of different measurements before and after scaling. 
Histogram of an experiment before (black line) and after scaling (dotted line) to 
match the signal distribution of another experiment (gray line).  
 
 
A homogenous microarray experiment exhibits the same overall signal distribution in 
different zones, as long as the zones that are chosen are large enough so that they are not 
subjected to the influence of the stripes with higher intensities as seen in figure 4.13.  
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Fig. 4.26  Histograms from different areas in one microarray experiment. 
Histograms at different areas (vertical fields of the width of 100 cells) taken from 
one experiment in the Latin Square dataset. Data not scaled. 
 
 
 
 
Many microarrays are not homogeneous, having different signal distributions in different 
areas. This can be due to a thermal effect, incomplete washing, diverse hybridization 
performance etc. One example is seen in figure 4.27. A clear intensity drift from left to right 
can be observed. The majority of the U133 microarrays of the leukemia dataset analyzed in 
chapter 5 had an uneven intensity profile, although not as pronounced as seen in figure 4.27. 
Another example is shown in the leukemia dataset analysis chapter. 
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Fig. 4.27  Microarray with horizontal intensity-drift.  
  
A) Microarray CEL-image, the colorbar denotes fluorescence intensities in logarithmic 
scale. An intensity drift from left to right can be observed, as well as the horizontal stripes 
common to U133 chips.  B)  Minimum intensity (red) and concurrent median intensity 
(blue) horizontal profiles. C) Histograms taken at different areas of the microarray (see 
figure 4.26). 
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The histograms in figure 4.27 C and analysis of microarrays from the leukemia dataset used in 
chapter 4 make it clear that an in-chip scaling is necessary. The intensity of the background in 
the microarray is subject to the same local scaling as the overall signal, as can be seen in 
figure 4.16, where overall mean signals are plotted against overall signal minima.  
It is thus possible to use the same algorithm to calculate a background surface, and a surface 
used to deduce the local scaling factors. The result of this local scaling of the microarray 
experiment shown in figure 4.27 is seen in figure 4.28 B. 
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Fig. 4.28 Histograms of different zones on one microarray before (A) and after local 
scaling (B), see also figure 5.2.   
 Microarray data in (A) was baseline corrected but not scaled. A clear deviation between 
histograms is visible but disappears through local scaling (B). 
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4.5 Probe Sequence Development 
4.5.1 Introduction 
 
To create a DNA microarray, oligonucleotides are immobilized onto the surface of a slide. 
These probes then hybridize with complimentary, fluorophore labeled target-DNA from a 
sample-solution. It is therefore essential to design a certain immobilized oligonucleotide so 
that only a target-DNA molecule with a matching sequence will hybridize with it in a highly 
selective way.  It is necessary to find a perfect match sequence for the hybridization with the 
target-DNA molecule that exhibits as many mismatches as possible towards other target 
sequences.  
A tool was created to facilitate the design of probe sequences for an animal species 
differentiation microarray under development at the Institute for Chemical and Biochemical 
Sensor Research (ICB).  This microarray was developed by V. Podsadlowski [111] for a fast 
genetic analysis of food samples using a real-time microarray hybridization and scanning 
device also developed at the ICB.  
 
 
4.5.2 Process of probe sequence development 
 
The first step in the development of optimal probe sequences is the alignment of the target 
sequences which are obtained after a PCR and meant for analysis. This is done using 
Clustal_W, a general purpose multiple sequence alignment program for DNA [112]. This 
program aligns the sequences, introducing gaps if needed. In a second step, a region in the 
aligned sequences is searched for which is the most different between the one sequence the 
probe molecule is meant to hybridize with and all the other sequences. If four samples are to 
be differentiated, the aligned sequence of sample 1 is taken and compared with the sequences 
of the other samples, then sample 2 is chosen and so forth. Tables 4.1 and 4.2 show 
subsequences (20 bases long) derived from the entire aligned sequence of two samples. A 
mismatch score is calculated for the 20 bases long excerpt by the algorithm in a moving-
window approach . 
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Tab. 4.1: Sequences of two samples aligned using Clustal W.  Mismatch scores are 
calculated in a 20-bases long moving window scheme. 
 
Sample 1      CCATGAGGACAAATATCATTCTGAGGAGCAACAGTCATTACCAACCTTCTCTCAGCAATT 
Sample 2      CCATGAGGACAAATATCATTCTGAGGAGCAACAGTTATTACCAATCTTCTCTCAGCAATC 
 
Sample 1      CCATATATTGGGACAAACCTAGTCGAATGGATCTGAGGGGGCTTTTCAGTAGACAAAGCA 
Sample 2      CCATACATTGGTACAAACCTAGTTGAATGAATCTGAGGAGGCTTTTCAGTAGACAAAGCA 
 
Sample 1      ACCCTAACCCGATTTTTCGCTTTCCACTTTATTCTCCCATTTATCATCGCAGCACTCGCT 
Sample 2      ACCTTAACTCGATTCTTCGCTTTCCACTTTATTCTACCATTCATCATTGCGGCACTTGCT 
 
Sample 1      ATAGTACACTTACTCTTCCTTCACGAGACAGGATCTAATAACCCAACAGGAATTCCATCA 
Sample 2      ATAGTACATTTACTCTTTCTTCACGAGACAGGATCCAATAACCCAACAGGAATCCCATCA 
 
Sample 1      GACGCAGACAAAATCCCCTTTCATCCTTATTATACCATTAAAGATATCTTAGGCATCTTA 
Sample 2      GATGTAGATAAAATTCCCTTTCATCCCTACTACACCATTAAAGATATTTTAGGCATCCTA 
 
Sample 1      CTTCTAGTACTCTTCTTAATATTACTAGTATTATTCGCACCAGACCTACTTGGAGACCCA 
Sample 2      TTCCTATTTCTCTTCTTAATAACACTAGTACTATTTGCACCAGACTTGCTTGGAGACCCA 
 
Sample 1      GATAACTACACCCCA 
Sample 2      GACAAATACACTCCA 
 
 
Tab. 4.2: Mismatch scores for five different 20 bases long excerpts from the sequence 
in table 1 at different positions. 
 
Score Sequence 1   Sequence 2 Mismatch position 
1 TCCTTCACGAGACAGGATCT TTCTTCACGAGACAGGATCC -*-----------------* 
8 ACAGGATCTAATAACCCAAC ACAGGATCCAATAACCCAAC --------*----------- 
13 CCTAGTCGAATGGATCTGAG CCTAGTTGAATGAATCTGAG ------*-----*------- 
17 CTCCCATTTATCATCGCAGC CTACCATTCATCATTGCGGC --*-----*-----*--*-- 
29 ATCTTA CTTCTAGTACTCT ATCCTA TTCCTATTTCTCT   ---*---*-*---*-*---- 
 
The weighting of the mismatch score for each mismatch is primarily based on an analysis of 
the position of the mismatch in the 20 bases long subsequence. It is known that mismatches at 
the border of the sequence affect a hybridization less than a mismatch in the center of the 
sequence. As can be seen in table 4.2, an aligned subsequence with a mismatch in its center 
scores higher than a subsequence with two mismatches near its borders. The location 
dependant weighting function has to take into account the above mentioned behavior. The 
function used in table 4.2, for example, rises linearly with growing proximity to the 
subsequence center; the score bsc,p for each basepair at the position p of the subsequence of 
length L is    
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One further consideration is the so called GC-content of an aligned subsequence. The GC 
base pair ineraction is stronger than the AT one, as one more hydrogen bridge is created 
(moving the equilibrium of the hybridization reaction farther in direction of the hybridized 
species). The chosen sequence should therefore also have a high GC content. 
Figure 4.29 shows the result of the mismatch score analysis of the comparison of a coney 
CytB-gene sequence with the CytB sequence derived from five different animals (pork, fallow 
deer, horse, rabbit, human) [111].  
 
 
 
Fig. 4.29 Mismatch scores for the comparison of a CytB coney sequence with the same 
gene from five other species. 
 
 Compared were subsequences of a 360 bases long CytB gene sequence. The optimal subsequence 
region is marked with a line at base number ~300.  
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Application of the tool showed an useful selection to have a mismatch score of at least 15 in 
all coney / other species comparisons  and a GC content of at least 45 %. It was shown during 
the design phase of the animal species differentiation microarray that the algorithm worked as 
predicted, facilitating the microarray development. Table 4.3 shows the results of food 
samples analyzed by the CVUA (Chemischen und Veterinär Landesuntersuchungsamt, 
Münster) and by means of the microarray developed at the ICB [111].  All animal species 
were detected correctly. 
 
Tab. 4.3 Results of food samples analzed by the CVUA and by means of the 
microarray developed at the ICB [111] 
 
Sample source identification 
by CVUA 
Identification using the microarray 
developed at the ICB 
haunch of venison venison 
wild boar roast wild boar 
haunch of hare hare 
deer medallions deer 
haunch of deer deer 
 
Some of the developed sequences are for the identification of origin for samples from the 
species horse, goat, buffalo, fallow deer, deer, sika deer, red deer, hare, coney, human and dog. 
4.6 Discussion of signal processing methods 
 
Almost all of the several hundred U133 microarrays analyzed contained artifacts. Their size 
and form varies substantially, from small round speckles or fine scratches up to large areas 
containing ten thousands of cells. Detection of these cells is important as their utilization in 
the calculation of the expression value for a certain probeset can have drastic consequences 
depending on the gene expression summary algorithm used. As the MicroArray Suite of 
Affymetrix does not provide for an automatic artifact detection scheme, the method developed 
in this work proves to be a good way to tackle this task in an easy and reliable way. The 
algorithms have been fine-tuned using hundreds of microarrays so that a minimal number of 
differentially expressed cells are flagged as being outliers. Outlier detection is done by 
calculating the deviation of a cell from the median signal of this cell over several microarrays. 
This implies that several microarray experiments have been made to gain the necessary 
amount of data. Median chips created by using measurements of different studies can differ 
from one another, the best and most reliable method therefore being the utilization of data 
from one and the same study for analysis and the creation of the medianchip. To provide for a 
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medianchip when only very few measurements are made, a library of medianchips can be 
created. A medianchip that has the closest fit to the new measurements can then be selected. 
The storage of medianchips can be easily done by using the developed microarray data 
management system. This management system was developed in accordance with the rules of 
the MIAME project approved by the Microarray Gene Expression Database group. 
Detailed information on the nature of the artifacts further provide quality measures giving 
information on the entire analysis process. One example is the absence of small round 
artifacts, previously found very often on microarrays, the reason being that scientists have 
switched from using powdered to non-powdered laboratory gloves when doing microarray 
experiments. These measures therefore provide information that can be helpful for the entire 
research process, the ultimate goal being the enhancement of the quality of the entire process 
and the beforehand reduction of the possibility of artifact creation.  
Unfortunately, U133 microarrays do not show a homogeneous signal distribution. There are 
horizontal stripes with higher signal intensities. These stripes make a more direct 
identification of abnormalities impossible. This includes the calculation of the background 
signals, as the U133 microarrays do not provide any direct means to measure it. A 
disadvantage of the Affymetrix method for background correction is the small number of 
anchor points available for the interpolation of the background signal, as the zones defined 
have to be large enough to evade the effect of the intensity stripes previously discussed (4x4 
zones are normally used). The developed method, on the other hand, uses the information of 
these anchor points as well as several hundred additional points provided by the checkerboard 
area of the microarray. The number of available data points makes a thin-plate interpolation 
possible. This method has shown to be well suited in interpolating noisy data in many sectors 
like meteorology and geology. The importance of a good area dependant background 
correction scheme becomes visible when regarding histograms from different areas on the 
microarray before and after background correction (see figure 5.2). The second step is the 
scaling. The MicroArray Suite scales the entire microarray by one value, ignoring area 
dependant differences in overall signal values. This area dependant discrimination is essential 
to match the different signal distributions present at different areas on a microarray. The 
developed method for the interpolation of background signals can also be used for the area-
dependant scaling of the data. When applied to several different microarray measurements 
from different series a good matching of histograms from different areas was observed. 
Application of the methods on replicate measurements provided by Affymetrix showed a 
clear improvement in signal quality. 
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5 Analysis of Leukemia Data 
5.1 Introduction 
 
A public pediatric leukemia dataset [86] was selected and analyzed to find a list of genes best 
suited to differentiate several subgroups of cancer and to analyze the effect of using different 
gene selection methods. Classification was done using a SVM classifier. The selection 
algorithms used were Fisher ratio, gene shaving, significance analysis of microarrays (SAM) 
and prediction analysis of microarrays (PAM). The different gene expression summary 
algorithms used include the Li-Wong model,  RMA and the MAS perfect match only model.  
5.2 Data Source and Composition 
 
The data used was first presented in the paper „Classification of pediatric acute lymphoblastic 
leukemia by gene expression profiling“  published in BLOOD, 15 October 2003, Vol. 102, 
Number 8 [86].  
As described in the leukemia chapter, the exact classification of the disease into several 
subgroups is essential for a tailored therapy and good survival prognostics. The pediatric 
acute lymphoblastic leukemia (ALL) dataset that has been analyzed can be subdivided into 
several sample subgroups. These groups differ in their cellular and molecular characteristics 
and also in their response to therapy. The leukemia subgroups contained in the dataset are 
shown in table 5.1. 
 
Tab. 5.1 Subgroup distribution of samples in the dataset 
Sample Type   Numbers
 T-ALL   14 
 B-Cell lineage:       
  BCR-ABL   15 
  E2A-PBX1   18 
  Hyperdiploid with more than 50 chromosomes 17 
  MLL    20 
  TEL-AML1   20 
  Others:     
    Novel   13 
    Hypodiploid   4 
    Normal_diploid   3 
    Pseudodiploid   8 
 Total Sample Number   132 
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The Novel-subgroup was found in an ALL study performed with U95 microarrays. This study 
is the predecessor of the above mentioned paper and was published in 2002 (“Classification, 
subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by 
gene eypression profiling”, Yeoh EJ, Ross ME, Shurtleff SA, et al., Cancer Cell, 2002; 1:133-
143) [113].  The new study analyzed here uses a subset of the data analyzed by Yeoh et al. 
The Novel subtype can also be seen in the data obtained using U133 microarrays. 
 
5.3 Preprocessing 
 
The gene expression value for each probeset was calculated using different methods. The data 
preprocessing consisted of the following steps: 
1. The same background correction and scaling methods were used as described by the 
authors of the different gene expression summary techniques. 
2. Data of one sample was scaled independently for each U133A and U133B chip to a 
trimmed mean of 250 and then combined.  
3. Genes having the following characteristics were discarded: 
o expression below 100 in all samples,   
o flagged as not present in more than half the samples (using the MAS flags), 
o being in saturation. 
4. Genes were auto-scaled. 
 
The Li-Wong, RMA and MAS pm only models were applied using the statistical software R 
[114]. 
 
5.4 Quality Aspects 
 
5.4.1 Time of measurement 
 
The date at which the sample was scanned is included in each Affymetrix CEL-file. It is 
possible to analyze if there is a relation between the information extracted from the data or 
about the data (e.g. sample subgroup) and the measurement time. The ideal measurement 
procedure would be to measure all samples randomly and as close as possible in time. 
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Fig.  5.1 Chart of measurement dates of the samples (color coded) and chip types
  (squares = U133A;  circles = U133B ). 
  
Measurement took place throughout three and a half months. A and B chips were scanned 
separately and some sample groups were scanned nearly completely as one block (Others and 
MLL samples U133A microarrays). The ideal would have been a complete random scanning of 
all samples to evade a possible influence of measurement time, although no apparent influence 
can be seen in this study. Samples are represented as colored circles or squares, some of these 
being drawn close to one another (some are not visible in their entire breadth). 
 
Both chips, the U133A and U133B, should be measured together. As can be seen in figure 5.1,  
some groups of samples were measured nearly completely in one block (e.g. MLL or Others). 
U133A and U133B chips were scanned at two different time intervals.  
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5.4.2 Homogeneity of Chips  
 
In-chip background and scaling can vary greatly. Background correction and scaling are 
essential, as can be seen in figure 5.2. Signal distributions at different location of chip JD-
ALD051 (MLL subgroup, B-chip) differ greatly before preprocessing. A background 
correction as is done by default in the MAS software helps considerably to make the overall 
signal distribution more homogeneous. An area-dependant scaling is also necessary to match 
the histograms but is not done by the MAS software and thus not provided for in the original 
data. 
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Histograms from the raw 
image. Histograms from 
different areas differ greatly, 
displaying the necessity for 
image preprocessing.  
 
 
 
 
Histograms after background 
correction. Histograms still 
have different maxima at 
different positions. 
 
 
 
 
Histograms after background 
correction and local scaling. 
The positions of the histogram 
maxima are the same and their 
values nearly equal. 
 
Fig. 5.2 Histograms from different sectors in measurement JD-ALD051 (MLL 
subgroup). Background correction and in-chip scaling are essential for 
making the data usable. 
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Fig. 5.3 Ratioimage of the microarray (logarithmic scale) discussed in figure 5.2. 
Clear differences in signal distribution are visible. 
 
5.4.3 GAPDH 3’ / 5’ Ratio 
 
RNA can degrade during cDNA synthesis. The result is first-strand cDNA containing a mix of 
truncated and full-length transcripts. Measurement of 5’-end and 3'-end fragments of a long 
RNA, here glyceraldehyde-3’-phosphate dehydrogenase (GAPDH), can give information on 
the quality of the RNA. The ratio of the 3' to 5' amplified fragments provides a direct 
indication of RNA integrity since in most cases RNA degradation starts in the 5'-end region of 
a RNA molecule. 
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Fig. 5.4  Boxplot of the GAPDH 3’/5’ ratios of all 132 samples. All samples have a 
ratio below 3. 
 
Quality control during creation of the dataset enforced the 3’ / 5’ ratio to be well below 3. 
More important, no trend for a specific ratio for a certain sample subgroup can be found. 
 
Analysis of Leukemia Data                                                                                                            76
 
5.4.4 Present Calls  
 
Analysis of the present calls of the samples showed that all U133A chips have higher present 
calls than U133B chips. This is usually the case as U133B chips contain more expressed 
sequence tags (ESTs), while U133A chips contain a higher amount of known gene sequences. 
Median present calls are 36% for U133A and 21 % for U133B chips in this study. Also, 
different sample subgroups neither had overall different present calls nor were the values time 
related (see figure 5.5). 
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Fig. 5.5 Percent of signals called present in U133A chips (circles) and U133B chips 
(squares). The fraction of present calls is higher in U133A chips as expected, 
with a mean around 35 % as observed in many other studies. U133B chips 
have a lower overall percentage as they contain many ESTs. 
 
 
5.4.5 Number of Affymetrix Outliers and Masked Cells 
 
The number of outliers as flagged by the MAS software is generally higher in U133B chips 
with a wider distribution. Two U133A samples have a higher number of outliers (JD-ALD109, 
TEL-AML1 subgroup and JD-ALD-052, MLL subgroup) but a normal amount of masked 
cells, baseline levels and signal distributions.  
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Fig. 5.6 Boxplot showing the number of Affymetrix outlier cells in different 
microarrays. 
 
The number of cells masked by the new algorithm (see chapter 4.2.2) is also higher in U133B 
chips. One U133A chip distinguishes itself by having nearly 35000 masked cells (marked as 
A in figure 5.7). This is a microarray with a very large artifact in the upper left corner (JD-
ALD416, E2A-PBX1 subgroup) which was already analyzed closer in chapter 4.3.2. It is 
therefore possible to select these kinds of microarrays automatically by monitoring the 
deviation concerning masked cell numbers from that of the rest of the population. 
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Fig. 5.7 Boxplot showing the number of masked cells in different microarrays. One 
microarray, marked as (A), contains a very large artifact (JD-ALD416, E2A-
PBX1 subgroup). It is analyzed closer in chapter 4.3.2. 
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Generally, there is no connection between the number of masked cells and the number of 
Affymetrix outlier cells.  
The authors of the original paper wrote “Microarray scan images were visually inspected for 
apparent defects […].”  ( [86] page 2952). It is interesting to note that the microarray denoted 
as (A) in figure 5.7 did not have any flagged cells in the raw data provided by the authors. 
Cells in the area of the artifact were thus probably also used for the calculation of the probeset 
specific gene expressions using the MAS software, although it is possible that the authors of 
the paper had used a different set of files with flagged cells. 
 
 
5.4.6 Relation between sample class and sample quality  
 
The relationship between samples as well as the relationship between variables can be 
visualized by using a principal component biplot in which the scores-plot as well as the 
loadings-plot of the principal component analysis are diplayed in the same diagram. Figure 
5.8 contains the bi-plots of all U133A as well as all U133B samples using their corresponding 
values of the quality criteria (scan-date, percentage present calls, 3’/5’ ratio, number of 
outliers). It can be seen that the number of present-calls is anti-correlated with the height of 
the 3’/5’ ratio, i.e. samples with a low ratio also have a high present call value thus being of 
overall good quality. Samples with below average quality have both high 3’/5’ ratios and low 
present call values. It is visible that there is no clear separation of any sample-subgroup exists. 
No subgroup can be discriminated from the rest of the samples by using quality measure alone 
or a combination of these. 
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A   
PCA Biplot showing U133A 
samples and quality criteria 
 
 
 
 
 
 
 
 
 
 
B   
PCA Biplot showing U133B 
samples and quality criteria 
(legend as seen under A) 
Fig. 5.8 Biplots created using quality measures.  No subgroup can be discriminated 
from the rest of the samples by use of any quality measure alone or a 
combination of these. 
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5.5 Gene Selection 
 
5.5.1 Introduction 
 
Not all sample subgroups are separated well using all genes for discrimination as can be seen 
in figure 5.9. The only subgroup falling entirely into one cluster is T-ALL, thus being clearly 
separated from all other samples, that is, members of the B-cell lineage. Most genes measured 
are not differentially expressed. The including of these non-informative genes in a classifier 
would only increase the amount of noise in the system. These genes therefore have to be left 
out. Even when regarding only those genes that are differentially expressed, it is important not 
to use too many genes. Although the apparent error rate (the proportion of  training tissues 
misclassified) of a classifier would decrease when using more informative genes, its error rate 
in classifying tissues outside of the training set would eventually increase. It is therefore 
necessary to select a few, highly selective genes for better discrimination [115]. This goes 
hand in hand with the desire to shrink the number of genes used for discrimination to make it 
possible to design a low-density diagnostic chip. Therefore, the target is to select a minimum 
number of genes suited to achieve the best separation of sample subgroups [116].  Four 
methods were used for gene selection, one being the calculation of the Fisher ratios of each 
sample subgroup against the rest of the samples. This provides genes that have the most 
different gene expression patterns between these two sample groups. The second procedure is 
the so-called gene shaving which clusters genes according to similar gene expression patterns 
across samples. The third and fourth are the significance analysis of microarrays (SAM) [85] 
and the prediction analysis of microarrays (PAM) [87] methods. The data was preprocessed as 
described in 5.3 if not otherwise described. 
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Dendrogram using Ward's method
 
Fig. 5.9 Dendrogram of all samples using all genes. Samples of the same subgroups 
do not necessarily fall into same clusters. Only T-ALL is clearly distinguished 
from all B-cell lineage samples. A gene selection procedure is necessary to 
increase sample subgroup separation.  
 
A SVM-classification (see classification chapter) using all genes provided a classification 
accuracy of 92.1%. A comparison with accuracies reached using fewer genes (see further 
below) also illustrates the necessity of gene-selection. 
 
MLL  blue 
TEL-AML1 magenta 
BCR-ABL  green 
Other  grey 
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5.5.2 Gene selection using Fisher ratio calculations 
 
Fisher ratios were calculated comparing one sample subgroup with the rest of the samples. As 
can be seen in figure 5.10, where an exemplary top 100 genes from each comparison are 
displayed, the overall quantitative pattern of expression of discriminating genes varied 
significantly between leukemia subtypes. Blocks of genes with clear up-regulation for each 
sample subgroup compared to the rest of the samples can be distinguished. The Other-
subgroup was divided into its own subgroups. 
 
 
-----------                                                                      BCR-ABL                                                                  ----------------------                                                                                          E2A-PBX1                                                                             ----------------------                                                                             Hyperdip_50                                                                             ----------------------                                                                                                           MLL                                                                                        ----------------------                                                                        T-ALL                                                       ----------------------                                                                                                     TEL-AML1                                                                                        ----------------------                                                                                                                                                    others                                                                                                                                    -----------
 
Fig. 5.10 Heatmap showing the gene expressions of the top 100 genes from every 
cluster selected by Fisher ratio. Others-subgroup consists of groups Novel, 
Normal_diploid, Pseudodiploid and Hypodiploid (in that vertical order). 
Colors denote standard deviation units. 
 
 
The top five genes from each comparison were selected, yielding a total of 35 genes. The 
mean signal difference and the Fisher’s separability criterion can be used to assess the 
homogeneity of the sample subgroups, gaining information that shows which subgroup 
separations could be problematic. 
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Fig. 5.11 Difference between the median signal of top 100 discriminating genes in one 
sample subgroup in relation to the rest of the samples and Fisher’s 
separability criterion for the top 100 genes.  
  
 The other-sample-group is splitted into its Novel, Normal_diploid, Pseudodiploid and Hypodiploid 
subgroups. High values for the Normal_diploid and Hypodiploid subgroups are to be regarded 
with caution as these groups only consist of three and four samples respectively.  
 
 
Values for the Other-subgroups have to be regarded with caution, as some only consist of 
three or four samples.  
 
 
 
5.5.3 Gene selection using Gene shaving 
 
Gene shaving was performed on the data selecting 200 clusters with highly covariant genes. 
Several groups of genes were found with an expression pattern highly selective for one certain 
leukemia subgroup (figure 5.12) as well as gene clusters with significantly varying expression 
patterns for BCR-ABL, E2A-PBX1, Hyperdiploid>50, MLL, T-ALL and TEL-AML1 and the 
Others-novel sample subgroups. The novel group was easily identified. Signal patterns of 
genes differentiating members of the rest of the Other samples found by gene shaving are less 
distinct.  
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Fig. 5.12 Heatmap of all samples (rows) and 8 groups of genes selected by gene shaving. 
Colors denote standard deviation units. 
 
Top 15 genes were selected from each cluster having the highest correlation with the cluster  
expression pattern.  
 
 
5.5.4 Gene selection using Significance Analysis of Microarrays (SAM) 
 
The utilization of SAM yielded a list of genes whose expression patterns are highly individual 
for each corresponding sample subgroup (see figure 5.13). Each subgroup was compared with 
the rest of the samples. The top genes of each comparison were selected using scores provided 
by SAM, resulting in 98 selected genes in total. 
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Fig. 5.13 Heatmap of all samples (rows) and 7 groups of genes selected by significance 
analysis of microarrays (SAM). Colors denote standard deviation units. 
 
 
5.5.5 Gene selection using Prediction Analysis of Microarrays (PAM) 
 
PAM was used to select the genes best suited for a discrimination of sample subgroups. The 
threshold was selected by analysis of the training- and misclassification-errors (see chapter 
3.5.8.3). The aim was to maximize the threshold and to minimize the errors and number of 
genes (see figure 5.14).  
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Fig. 5.14 Training- and misclassification errors for different thresholds. A threshold of 
7 was selected, yielding a total of 336 genes. 
 
A threshold of 7 was selected, yielding a total number of 336 genes which are suited well to 
differentiate different sample subgroups. The number of genes was then further downsized to 
achieve a selection with an amount of genes comparable to the one achieved with the other 
methods. This was done using the gene-scores for each centroid yielding a total of 89 selected 
genes. 
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Fig. 5.15 Heatmap of all samples (rows) and 7 groups of genes selected by prediction 
analysis of microarrays (PAM). Colors denote standard deviation units. 
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5.5.6 Separation of sample subgroups using selected genes 
 
Highly selective genes for a better discrimination of sample subgroups were selected from the 
Fisher ratio and gene shaving clusters. The selected top 5 genes of each Fisher ratio cluster 
where supplemented with certain genes from gene-shaving clusters as these were the most 
different compared to the Fisher ratio selection as can be seen in table 5.2. Those genes from 
gene shaving clusters were used that were unique and had references in online databases 
denoting them as being cancer related. This selection of these 66 genes made a better 
subgroup separation possible. 
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Dendrogram using Ward's method
 
Fig. 5.16 Dendrogram of all samples using 66 genes. Most sample subgroups fall into 
their own clusters. The two BCR-ABL samples marked with the arrow also 
have a hyperdiploid karyotype and are therefore also clustered correctly. 
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The heterogeneous character of the BCR-ABL subgroup was already mentioned in the original 
data publication paper [86]. Two cases of BCR-ABL (marked with an arrow in figure 5.16) 
have a karyotype showing the presence of both the Philadelphia chromosome and a 
hyperdiploid karyotype consisting of more than 50 chromosomes, including trisomy of 
chromosomes X and 21. They are therefore clustered correctly according to their karyotype.  
This can also be seen in figure 5.17.  
 
 
 
Fig. 5.17 Plot of samples using the first three principal components. The disperse 
distribution of BCR-ABL samples is visible (with the two BCR-ABL samples 
having hyperdiploid karyotype marked with arrows [A], and a third sample 
often misclassified as member of the hyperdiploid>50 subgroup, marked with 
arrow [B]).  
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5.5.7 Selection of genes for differentiation of the Other-subgroups 
 
Samples in the group denoted as Others have normal, pseudodiploid and hypodiploid 
karyotypes. Some of these samples have a distinct gene expression profile and have been 
defined as members of the Novel subgroup in the original paper [86]. This novel subgroup 
could also be identified using gene-shaving. A clear grouping of the samples from different 
Other-subgroups is visible using the top 5 genes selected by a Fisher ratio calculation 
comparing one Other-subgroup with the rest of the Other-samples (see figure 5.18). 
 
 
 
Fig. 5.18 Separation of samples from different Other-subgroups using 20 genes in total, 
selected by one against the rest Fisher ratio calculation. 
 
 
It is also possible to differentiate between samples from the Novel group and all other samples 
using the genes from the gene shaving cluster 7 (figure 5.12). 
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Fig. 5.19 Separation of samples from the Novel-subgroup from all other samples using 
86 genes selected by gene-shaving (genes from cluster 7 in figure 5.12). 
 
 
As a differentiation and cross-validation of some subgroups of the Other sample-group is not 
feasible because they only contain three or four samples, only one classifier for the 
differentiation of the Novel subgroup was created. Samples in this subgroup can be separated 
from the rest of the samples in the Other-group using one gene. 
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Fig. 5.20 Separation of samples from the Novel group from the rest of samples of the 
Other group using only one gene. Pyramids: Samples in the Novel group; 
Circles: rest of the samples in the Other-group. Values denote the gene 
expression in standard deviations. 
 
A good separation of the rest of the Other-subgroups (Hypodiploid, Normal_diploid and 
Pseudodiploid) seems possible. More samples of this category should be analyzed to 
determine the feasibility of this discrimination. As can be seen in figure 5.21, Hypodiploid, 
Normal_diploid and Pseudodiploid samples are separated using genes selected by Fisher ratio 
calculations. 
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 A   Separation of 
Hypodiploid samples 
(pyramids)  from the 
rest. 
 
B  Separation of 
Normal_diploid 
samples (pyramids) 
from the rest. 
 
C  Separation of 
Pseudodiploid 
samples (pyramids) 
from the rest. 
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Fig. 5.21 (A) Separation of the four Hypodiploid samples from the rest of the samples 
(128 in total); the diagonal between the first and second principal component 
is shown. (B) Separation of the three Normal_diploid samples from the rest of 
the samples (129 in total). (C)  Separation of the eight Pseudodiploid samples 
from the rest of the samples (124 in total), each time using genes selected by 
Fisher ratio calculations  
 
5.5.8 Comparison of different selection methods 
 
Each method for gene selection yielded a different gene-list. The top genes from each 
selection were compared with one another to gain information on the resemblance of the 
selections. 
 
Tab. 5.2A Resemblance of gene lists selected using different methods (top 100 genes) 
 
A   Percentage of genes contained in 
  
  Fisher Ratio SAM PAM Gene-Shaving 
Fisher Ratio 100 63 53 37 
SAM 45 100 56 36 
PAM 45 65 100 35 
G
en
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Gene-Shaving 25 33 30 100 
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Tab. 5.2B Classification accuracies using the top genes from each selection  
 
 B   
Fisher 
Ratio SAM PAM 
Gene-
Shaving 
Accuracy 98.5% 98.2% 96.8% 93.4% 
7 groups 
Number of genes 70 98 89 105 
Accuracy 99.4% 99.1% 98.8% 96.0% 
6 groups 
Number of genes 60 84 88 90 
 
The selection process was done using all samples. 30% of the samples were then left out in cross 
validation for classification. Classification was done with a linear-SVM classifier. The number of 
genes was selected using selection scores provided by the different algorithms. Classification was 
done using all groups and only six groups (leaving out the Others sample subgroup). This was done 
as the centroid for this seventh class only yielded one gene. 
 
It is interesting to note that the highest similarity in selection for the SAM list lies in the PAM 
list and vice versa. The highest accuracy when classifying the samples using a linear SVM 
classifier (see also chapter 5.6) was achieved by using the Fisher ratio selection, followed by 
the SAM and the PAM selections. The classification of the Other-samples leads to a high 
misclassification rate using the PAM list, as only one gene was selected by the algorithm in 
the shrunken centroid of this sample subgroup. To confirm the order of the classification 
accuracies, classifications were performed using only six sample subgroups and discarding 
the samples of type Other. The same order of accuracies was observed, as can be seen in table 
5.2B. It is to be noted that the differences in accuracies are only slight ones (except for the 
gene shaving selection) and the different methods perform very similarly using this dataset. 
The classification by PAM itself yielded a classification accuracy of  96.3%. 
 
5.6 Sample Classification 
5.6.1 Introduction 
 
Cross validation was used to evaluate the accuracy of a classification model. 30% of each 
sample subgroup were left out in the training of the classifier and classified afterwards (38 
samples in total). This was done 100.000 times.  A linear support vector machine classifier 
was used for classification. The routines used are from the OSU SVM toolbox (v3.0) for 
Matlab by Junshui Ma, Yi Zhao, and Stanley Ahalt, Department of Electrical and Computer 
Engineering, Ohio State University. 
 
Analysis of Leukemia Data                                                                                                            93
5.6.2 Main Classifier 
 
The mean misclassification rate using the 66 genes selected  in 5.5.6 was 1.2 %. The main 
erroneous classifications being  
 
1. classifying a BCR-ABL sample as Hyperdiploid>50, 
2. classifying an Other sample as TEL-AML1. 
 
96% of the misclassified BCR-ABL samples were the two samples that also had the 
hyperdiploid>50 karyotype. Only one other BCR-ABL sample was misclassified (sample bcr-
abl#3). To minimize this error, two further classifiers were appended to the classification 
process. 
 
5.6.3 BCR-ABL classifier 
 
Fisher ratio calculations were performed comparing BCR-ABL samples with hyperdiploid>50 
samples and the top10 genes were selected.  
 
 
Fig. 5.22 Plot of the first three principal components using ten genes selected by Fisher 
ratio calculations using BCR-ABL and hyperdiploid>50 sample subgroups 
only. 
 
All samples previously classified as BCR-ABL could now be classified as hyperdiploid>50. It 
is to be noted that a classification of the two BCR-ABL samples marked in figure 5.16 and 
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5.17 as members of the hyperdiploid>50 sample subgroup is also correct but as the BCR-ABL 
translocation has a worse survival prognostics, a clear identification of a sample as being a 
member of this group is essential to administer the best treatment possible. The third BCR-
ABL sample also classified this way should be analyzed further to determine if it does not 
actually also have these sorts of genetic lesions. The differentiation of BCR-ABL from 
Hyperdiploid>50 samples in this step had an accuracy of 100%. This makes it possible to 
define those BCR-ABL samples having a hyperdiploid>50 karyotype with an accuracy of 96%.  
 
5.6.4 TEL-AML classifier 
 
Fisher ratio calculations were performed comparing TEL-AML samples with the Other-
subgroup samples. The top genes were selected and supplemented with genes from the gene 
shaving clusters assigned to these two sample groups.  
 
Fig. 5.23 Plot of the first three principal components using 11 genes selected by Fisher 
ratio calculations and gene shaving clusters using TEL-AML1 and Other 
sample subgroups only. 
 
Utilization of 11 genes produced an overall classification accuracy of 100%. 
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5.6.5 Novel-group Classifier 
 
The classification of Novel-samples with an accuracy of 100% was added to the classification 
chain, providing a means to classify a sample into 8 different groups (BCR-ABL, E2A-PBX1 , 
Hyperdiploid>50, MLL, T-ALL, TEL-AML1, Novel and Others ). 
 
 
5.6.6 Final sample subgroup classification  
 
The main classifier was used to make a preliminary classification. All samples classified as 
hyperdiploid>50 or TEL-AML1 were then subjected to their respective follow-up classifier. 
This resulted in an average accuracy of class assignment in cross-validation using a total of 88 
genes of 99.97%, with a range from 99.9% to 100%.  
 
 
Tab. 5.3 Subgroup prediction accuracies using 88 genes selected with Fisher ratio 
calculations and gene shaving. 
 
 
Subgroup Apparent Accuracy Sensitivity Specificity 
BCR-ABL 100.0 100.0 100.0 
E2A-PBX1 100.0 100.0 100.0 
Hyperdip50 100.0 100.0 100.0 
MLL 99.8 99.8 100.0 
T-ALL 100.0 100.0 100.0 
TEL-AML1 100.0 100.0 100.0 
Others 99.8 99.9 100.0 
Novel* 99.8 99.9 100.0 
 
The differentiation into the Novel group was done using only the samples 
previously classified as being members of the Others-subgroup. This 
differentiation of the Others-subgroup had an accuracy of 100%. 
 
 
5.7 Feature selection bias and true accuracies 
 
 
The performance of a classifier using a subset of genes is assessed by using cross validation 
as described above. If the subset of genes was selected using all samples, there is a selection 
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bias, leading to too optimistic classification accuracies. A better estimate of true accuracies 
can be gained by applying the feature selection itself inside a cross-validation scheme, i.e. 
using a group of samples for selection of genes suited the best for class separation and 
applying a classifier using these genes on the rest of the samples that were completely hidden 
in the selection process [78]. A leave-one-out approach makes it possible to implement this 
procedure when working with a small number of samples that is common when dealing with 
microarray data.  
70% of the samples of the leukemia dataset were used to select genes through Fisher ratio 
calculation in each of the 30 performed iterations. These genes were then used  to perform the 
above mentioned classifications of the 30% of the samples completely withheld previously.  
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Fig. 5.24 Misclassification rates for the classification of previously withheld samples. 
Boxplots show upper and lower 25th percentile. 30% of the samples were withheld from the gene-
selection procedure. A certain number of genes was  selected and classification then performed on 
the 30% of the samples previously left out. This procedure was performed 30 times for each 
number of genes. 
 
 
An accuracy of 98.1% using 120 genes could be reached using this method of increased 
selection bias correction. 
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Tab. 5.4 Subgroup prediction accuracies using 120 genes selected with Fisher ratio 
calculations after selection bias correction 
 
Subgroup True Accuracy Sensitivity Specificity 
BCR-ABL 88.4 88.4 100.0 
E2A-PBX1 100.0 100.0 100.0 
Hyperdip50 100.0 100.0 99.1 
MLL 100.0 100.0 100.0 
T-ALL 97.6 97.6 100.0 
TEL-AML1 100.0 100.0 100.0 
Others 100.0 100.0 100.0 
 
5.8 Effects of using different gene expression summary algorithms 
 
The different gene expression summary algorithms used were the Li-Wong model, the RMA 
model, the MAS perfect match only model and the MAS model implemented in the 
BioConductor packages for R. The same background correction and scaling methods were 
used as described by the authors of the different gene expression summary techniques.  
Several probesets are located on the U133A as well as the U133B chip. The gene expression 
summary algorithm should calculate very similar values for these replicates when regarding 
one and the same sample. Replicate pairs were used to assess this similarity of calculated 
signals. The mean relative difference in signal between replicates was calculated to estimate 
how good each summary technique performed. Figure 5.25 shows that the RMA method 
performed best, with a mean deviation of 0.2%. The MAS method performed worst, with a 
mean deviation of 1.3%.  
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Fig. 5.25 Mean deviation of the signals of duplicate probesets in percent. Boxplots 
show upper and lower 25th percentile. 
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These findings concur with the results of Speed et al. [117]. The MAS PM only method, 
which is the same as the MAS method without subtraction of the MM value (or rather the IM, 
Ideal Mismatch value, see [89]), produces data with clearly lower signal deviations between 
replicates. This concurs with the findings of Irizarry et al. that a subtraction of MM signals 
increases the noise [118]. The Li-Wong method also performs worse than the RMA method. 
Although this also concurs with the findings of Calogero et al. [119] and Irizarry (RMA 
having better precision), the reason for such strong differences could also be that not enough 
microarrays for a good convergence of  the Li-Wong model had been used. The authors of the 
method suggest using at least 10 microarrays. Eleven microarrays were used to generate the 
data, as a higher number was not possible due to memory problems during computation.  
Results of a comparison of the genes selected by Fisher ratio can be seen in table 5.5. There 
are great differences in selection, at least when regarding the top 20 or even the top100 genes 
for each class. 
 
 
Tab. 5.5 Percent of genes being the same in the top 20 genes found by Fisher ratio 
one – against – rest selection using different gene–expression gene 
expression summary algorithms 
 
Genes compared with top 20 genes from 
 
Li-Wong MAS PM only MAS RMA 
Li-Wong 100% 54% 52% 49% 
MAS PM only 54% 100% 62% 51% 
MAS  52% 62% 100% 51% 
To
p 
20
 g
en
es
 
fr
om
 
RMA 49% 51% 51% 100% 
  
Fisher ratios were calculated using samples from one group and compared with all other samples. The 
seven resulting groups of top 20 genes were compared individually with the same group calculated, 
using a different summary algorithm. Results were then combined to create the overall percentage of 
similarity. This overall percentage is very similar to the percentages in single comparison groups. The 
percentages stay on the overall same level if the top 100 genes are compared (deviation of  ± 2-
3 %points). 
 
 
Samples were classified using a linear SVM classifier using genes selected by Fisher ratio 
calculations (20 genes for the differentiation of each subclass against the rest) and by PAM 
(225 genes selected by score). As PAM had difficulties selecting genes for the centroid of the 
class Others, only six sample subgroups were used in this analysis. Genes were selected using 
the entire dataset. 
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Tab. 5.6 Misclassification rates using a linear SVM classifier applied to six samples 
subgroups (Others omitted) using genes selected by Fisher ratio criterion and 
PAM.  
 
 Li-Wong MAS PM only RMA MAS 
Fisher Ratio, 60 genes 2.0% 1.2% 1.4% 1.3% 
PAM, 225 genes 1.6% 1.5% 2.3% 1.9% 
 
The classifier performed best when using the data generated by the MAS PM only method in 
both the Fisher ratio and PAM case. The other method’s order varies depending on the gene 
selection procedure used. The MAS perfect match only method yields the best results in 
classification and the RMA method in signal reproducibility; these methods are thus to be 
favored. 
 
5.9 Discussion of leukemia data analysis  
 
Data analysis can only yield informative results if the data used has the needed quality [120, 
121]. Analysis of quality parameters has shown the leukemia dataset to be of overall good 
quality. One drawback is the time sequence in which the samples were measured [69]. U133A 
and U133B chips were measured at completely separate time intervals and some sample 
subgroups were not shuffled with other samples well enough and can be found in almost 
completely continuous blocks. Although these facts did not prove to have any detectable 
effects on the data or class assignment, a correct implementation of the measurement 
sequence could have easily been done without any further cost.  
Signal distributions on the microarrays often showed an area dependant background and 
signal intensity drift. This drift was more pronounced than in other measurement series like 
the Latin Square dataset [105], a CD4 Lymphocytes dataset [96] or a proprietary dataset 
containing several hundred measurements from Haferlach et al.[97]. As could be shown with 
histogram comparisons, a global scaling, as performed by the authors of the original dataset, 
is not enough to compensate for these scaling differences. These different background and 
scaling values can be accounted for using the novel methods created in this work.  
Further, large artifacts could be found in the data. These cells were not flagged in the original 
CEL-files and were thus incorporated in the downstream analysis using the MicroArray Suite. 
The artifacts could be easily found using the novel, automatic detection scheme developed. 
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As expected, the use of all genes for class separation yielded worse results than when using a 
subset of genes. This is only logical, as most genes do not show any differential expression. 
Including them in the class separation procedure means incorporating a higher noise 
component, barely contributing to the net informative signal [122].  
Several different gene selection algorithms were used to select the differentially expressed 
genes, yielding several groups of genes with an expression pattern highly individual for one 
certain leukemia subgroup. Gene lists created using these methods differed from one another 
as the methods are based on different statistical methods. The most different list in 
comparison with the other lists was created by the gene-shaving procedure. This coincides 
with the fact that this method was the only one used without the a priori class assignment 
information. The preliminary classification results using a linear SVM classifier showed the 
gene lists selected by Fisher’s ratio calculations, SAM and PAM, to perform similarly. The 
classification using genes selected by gene-shaving performed worse, showing that the 
selected genes are less well suited for class separation than those selected by the other 
methods. This fact can be attributed partially to the lack of a priori knowledge [123] but also 
infers a selection of subsets of genes with coherent expression patterns and large variation 
across subgroups which were not optimal. In gene-shaving, each shaving sequence starts with 
the entire expression matrix which is then shaved down to a minimal cluster size. The 
adequate size of a cluster is derived from the gap estimate [84]. This estimate was not optimal 
at all the times, leading to clusters that included less predictive genes which might also have 
contributed to the worse classification results.  
The Novel sample-subgroup previously defined by Yeoh et al. [113] could be clearly seen 
when using gene-shaving. Using the genes hereby selected made it possible to separate these 
samples from all other samples in the dataset.  A separation of the different Others sample-
subgroups seems possible but could not be further analyzed due to the lack of enough samples. 
The promising preliminary class separation results speak in favor of analyzing further samples 
of these types.  
The dataset also included two samples which were classified as BCR-ABL samples and also 
had a hyerdiploidity with more than 50 chromosomes. These samples were primarily 
classified as members of the hyperdiploid>50 group. Although this classification is 
molecularly correct, it was defined as a misclassification as the detection of the BCR-ABL 
status is far more important due to less good survival predictions for this leukemia subgroup 
[3]. Including these two samples into the study therefore made an evaluation of classification 
rates more difficult but also helped make it more realistic, as these kind of samples can also 
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appear in real life diagnostics. A detection of these two samples that have a BCR-ABL as well 
as a hyperdiploid>50 status was only possible whenever the gene selection was done using all 
samples. This selection procedure introduces a selection bias as those samples which are to be 
classified are also used in the selection step [78]. This bias can be accounted for by 
implementing the feature selection step into the cross-validation routine. The overall 
classification accuracy dropped from 99.9% using 88 genes to 98.1% using 120 genes 
selected in this unbiased manner. The latter value is a more realistic estimate of the 
classification accuracy. Although a 100% accuracy is desired, the reality shows that complex 
cancer subtype classifications like the one at hand frequently fall short of this goal. It will 
have to be determined what level of diagnostic accuracies is needed to move this 
biomolecular approach into a clinical setting. One major advantage of these methods over 
classical diagnostic techniques like cytogenetic analysis is that their accuracies do depend far 
less on the level of expertise of the practitioner. Although the classification might be 
improved by the use of more selected genes that are informative, raising their numbers does 
not only hamper the creation of a low-density chip but it is also difficult to gain the license 
rights needed to use all of these genes for a certain task or a certain device [124]. 
Analysis of different gene expression summary algorithms showed the MAS perfect match 
only approach to yield more reproducible values than the MAS method. This concurs with the 
opinion of Naef et al. [62] and others that the expression measure should only be based on the 
PM signal.  
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6 Summary and Outlook 
 
 
The life sciences are currently undergoing a rapid revolution that is driven by large-scale 
genome sequencing, advances in structural and chemical biology, bioinformatics, 
chemometrics, imaging technology and bioanalytics. These disciplines have long existed as a 
collection of knowledge fields with well-defined territories but are now merging together to 
form new, powerful interdisciplinary domains. One of these new domains deals with the 
measurement of gene-expressions by quantitative analysis of the amount of the corresponding 
mRNA-molecule-content in cells. This bioanalytic technique, combined with state of the art 
chemometrics and bioinformatics, makes it possible not only to gain information on the role 
of certain genes in diseases like cancer, but also to classify unknown samples as being, for 
example, members of a certain cancer subtype. This molecular approach makes it possible to 
use specially designed therapies to maximize the rate of survival of cancer patients.  
Methods were developed in this work dealing with the complete processing chain used for the 
analysis of Affymetrix U133 DNA biosensor data. The aim was to increase the overall 
quality of the signals derived from microarray experiments, to find indicators applicable in 
quality management and to select diagnostic markers for the differentiation of pediatric 
leukemia cancer subtypes as one example application.  
A novel method for the calculation and subtraction of background signals and signal scaling 
was created based on thin plate-spline interpolation. Many microarrays exhibit spatially 
inhomogeneous signal intensity distributions. This can be due to thermal effect, incomplete 
washing, diverse hybridization performances etc. It is important to correct these deviations in 
order to make signals from different parts of the microarray comparable. The developed 
methods use the information of several hundred data points provided by the border area of the 
microarray. The number of available data points makes a nonlinear interpolation possible. 
This method has shown to be well suited in interpolating noisy data without giving rise to 
overfitting. The application of the interpolation method to calculate the area dependant 
background signal and the deviations in signal scaling made it possible to improve the overall 
signal quality of Affymetrix U133 microarrays. 
The data used was handled using a newly developed microarray data management system 
combining a SQL database and a file server with Matlab.  This system made it possible to 
store all data as well as analysis results in a safe and reliable way and is compliant with the 
MIAME standard. This data included quality measures calculated using novel methods, one 
main aspect being the automatic detection of signal artifacts on microarrays. This constitutes a 
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major enhancement as the MicroArray Suite of Affymetrix does not provide for an automatic 
artifact detection scheme. Almost all of the several hundred U133 microarrays analyzed 
contained artifacts. Their size and form varies significantly - from small round speckles or 
fine scratches up to large areas containing ten thousands of cells. The detection of these cells 
is important as their usage can have drastic consequences in the calculation of the expression 
value of the corresponding gene. The developed methods are able to detect these artifacts in a 
fast and reliable way and were fine-tuned to flag only a minimal number of differentially 
expressed cells as outliers. Detailed analysis of the artifacts provides information on the 
quality of the measurement which can be used to raise the quality of the entire analysis 
process. Artifact detection is achieved by using data from several microarrays, combining 
these signals to a virtual microarray containing the median values of same cells from all 
sensors. It is possible to detect anomalies on a microarray by comparing it with this median-
microarray. Detection of known and previously unknown artifacts showed this procedure to 
be very reliable.  
Microarray measurements of leukemia samples were used to select a group of genes suited 
best for differentiation of seven pediatric leukemia subtypes (BCR-ABL, E2A-PBX1, 
Hyperdiploid with more than 50 chromosomes, MLL, T-ALL, Others). A classification 
accuracy of 98.1% was achieved using 120 genes, performing a rigorous cross-validation by 
also including the gene selection process in the cross-validation procedure. Otherwise a 
potentially large selection bias, i.e. an optimistically biased error assessment, might arise. 
Different selection methods were compared, showing that Fisher ratio calculation, SAM and 
PAM perform similarly when applied to the pediatric leukemia dataset. Gene-shaving 
performed worse as it does not contain a priori class assignment knowledge. The Novel 
sample subgroup previously defined by Yeoh et al. [113] was found using gene-shaving. It 
was possible to separate all samples of this subgroup from all other samples using the genes 
selected by this method. 
Analysis of different gene expression summary algorithms (MAS, MAS PM-only, Li-Wong-
model, RMA) showed the MAS PM-only approach to yield more reproducible values than the 
MAS method. This concurs with the opinion of Naef et al. [62] and others that the expression 
measure should only be based on the PM signal. Further, the MAS PM-only as well as the 
RMA methods are good choices to achieve low deviation between replicate measurements and 
good classification results.  
It will have to be determined what level of diagnostic accuracies is needed to move this 
biomolecular approach of cancer detection and classification into a clinical setting, especially 
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as it may also be difficult to gain the license rights needed to use certain genes for a certain 
task or a certain device. But there is no doubt that DNA biosensors based on the Affymetrix 
technology will be used in clinical diagnostics in the near future. 
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